Piramal Critical Care collaborates with Blue-Zone to launch innovative waste anaesthetic gas recycling initiative.
Piramal Critical Care, a leading provider of inhalation anaesthetics, has partnered with Blue-Zone Technologies, a pioneer in anaesthetic gas recycling, to launch a groundbreaking initiative aimed at reducing the environmental impact of waste anaesthetic gases. This innovative collaboration seeks to address the significant problem of anaesthetic gas waste, which contributes to greenhouse gas emissions and poses a threat to the environment.
The partnership involves the deployment of Blue-Zone’s patented anaesthetic gas recycling technology, which captures and recycles waste anaesthetic gases, thereby reducing the amount of these potent greenhouse gases released into the atmosphere. This technology has the potential to significantly decrease the carbon footprint of healthcare facilities and contribute to a more sustainable future.
Under the terms of the agreement, Piramal Critical Care will work closely with Blue-Zone to promote and implement the anaesthetic gas recycling technology in healthcare facilities across the United States and Europe. The company will leverage its extensive network and expertise in the field of inhalation anaesthetics to raise awareness about the importance of anaesthetic gas recycling and the benefits of this innovative technology.
The recycling process involves the use of a specialized device that captures the waste anaesthetic gases and recycles them, resulting in a significant reduction in greenhouse gas emissions. This technology has been shown to be highly effective, with the ability to capture up to 90% of waste anaesthetic gases. By reducing the amount of these gases released into the atmosphere, healthcare facilities can significantly decrease their environmental impact and contribute to a more sustainable future.
The partnership between Piramal Critical Care and Blue-Zone Technologies is a significant step towards reducing the environmental impact of anaesthetic gas waste. The collaboration demonstrates the commitment of both companies to sustainability and their dedication to providing innovative solutions that prioritize the well-being of both patients and the environment. As the healthcare industry continues to evolve, partnerships like this one will play a crucial role in shaping a more sustainable future for generations to come. With the potential to significantly reduce greenhouse gas emissions, this initiative has the potential to make a substantial impact on the environment and public health.
Glenmark Pharmaceuticals sets sights on FY28 for debut of oncology drugs and expansion of profit margins, reports ETPharma.
Glenmark Pharmaceuticals, a leading Indian pharmaceutical company, has expressed confidence that its cancer drug, Trastuzumab Rezetecan (SHR-A1811), will enter licensed markets by FY28, driving an improvement in both gross and EBITDA margins. The company has guided for an EBITDA margin of 23% for the ongoing fiscal year and expects its higher-margin oncology assets to lift profitability. Trastuzumab Rezetecan, a HER2-targeted ADC, was in-licensed from China’s Hengrui Pharma in September 2025 for an upfront payment of $18 million and milestone payments of up to $1.093 billion.
Glenmark’s Chairman and MD, Glenn Saldanha, stated that the company’s oncology assets, including Trastuzumab Rezetecan and aumolertinib, will bring meaningful gains from FY28, driving long-term growth for the company. The company has also obtained exclusive rights for select markets, including India, and is exploring the treatment of HER2-positive cancers, such as non-small cell lung cancer (NSCLC) and breast cancer.
In addition to oncology, Glenmark’s leading respiratory asset, Ryaltris, is on track to become a $100 million brand on a moving annual basis. The company is also progressing well with its $1.9 billion out-licensing deal with AbbVie for the cancer asset ISB 2001, with Phase II trials expected to begin by the end of the current calendar year.
Glenmark has a net cash position of around Rs 600 crore and has reiterated its target to reduce gross debt to zero by March 2026. The company’s innovation spin-off, IGI, has an annual cash burn of $70 million. Commenting on the Union Budget 2026-27 announcement of Biopharma SHAKTI, a scheme to boost capacity creation for biologics and biosimilars, Saldanha said it is a positive development for the industry, although Glenmark does not currently have in-house manufacturing for biologics.
Overall, Glenmark is poised for growth driven by its oncology assets, and the company is confident that its strategic decisions will yield meaningful gains from FY28. With a strong focus on innovation and a robust pipeline of products, Glenmark is well-positioned to drive long-term growth and expansion in the pharmaceutical industry. The company’s commitment to reducing debt and increasing profitability is also expected to yield positive results, making it an attractive player in the Indian pharmaceutical sector.
HOSMAC has designed Cipla’s Breathefree Lung Wellness Centre in Mumbai, focusing on adaptive reuse and a wellness-centric approach, as reported by Prop News Time.
HOSMAC, a renowned healthcare design and consulting firm, has successfully designed Cipla’s Breathefree Lung Wellness Centre in Mumbai. The centre is a testament to HOSMAC’s expertise in creating healthcare facilities that prioritize patient-centric care and wellness. The design of the centre emphasizes adaptive reuse, transforming an existing building into a state-of-the-art lung wellness centre.
The Breathefree Lung Wellness Centre is a 5,000-square-foot facility located in the heart of Mumbai. The centre offers a comprehensive range of services, including lung function testing, pulmonary rehabilitation, and patient education. The design of the centre is centered around the concept of “wellness-led care,” which focuses on promoting overall well-being and preventive care rather than just treating illnesses.
HOSMAC’s design team worked closely with Cipla to create a space that is both functional and aesthetically appealing. The centre features a modern and sleek design, with ample natural light and ventilation. The interior design elements, including the color scheme and furniture, are carefully selected to create a calming and soothing atmosphere, conducive to patient recovery and wellness.
One of the key highlights of the centre is its emphasis on adaptive reuse. The existing building was transformed into a lung wellness centre, minimizing waste and reducing the environmental impact of the project. The design team worked closely with the existing structure, incorporating sustainable design principles and materials to create a energy-efficient and eco-friendly facility.
The Breathefree Lung Wellness Centre is equipped with cutting-edge technology and medical equipment, ensuring that patients receive the best possible care. The centre also features a team of experienced healthcare professionals, including pulmonologists, physiotherapists, and nutritionists, who work together to provide comprehensive care to patients.
The centre’s design and services are tailored to meet the specific needs of patients with lung diseases, such as chronic obstructive pulmonary disease (COPD) and asthma. The centre offers a range of programs and services, including pulmonary rehabilitation, smoking cessation, and patient education, to help patients manage their condition and improve their overall quality of life.
Overall, the Breathefree Lung Wellness Centre is a shining example of HOSMAC’s expertise in designing healthcare facilities that prioritize patient-centric care and wellness. The centre’s emphasis on adaptive reuse, wellness-led care, and sustainable design principles makes it a unique and innovative healthcare facility in Mumbai. With its state-of-the-art technology, experienced healthcare professionals, and comprehensive range of services, the centre is poised to become a leading destination for lung wellness and care in the region.
S&P Global Upgrades Biocon Biologics’ Credit Rating to ‘BB+’ with a Stable Outlook, Reports IndiaMedToday
S&P Global Ratings has upgraded the long-term issuer credit rating of Biocon Biologics, a subsidiary of Biocon Limited, to ‘BB+’ from ‘BB’. The rating agency has also maintained a stable outlook for the company. This upgrade is a testament to Biocon Biologics’ strong business profile, driven by its robust product portfolio, expanding global presence, and significant investments in research and development.
The ‘BB+’ rating reflects Biocon Biologics’ established position in the biosimilars market, with a diverse portfolio of products across diabetes, oncology, and immunology. The company’s commitment to innovation and quality has enabled it to build a strong reputation in the industry. S&P Global Ratings noted that Biocon Biologics’ revenue growth is expected to remain robust, driven by the increasing demand for biosimilars globally.
The rating agency also highlighted the company’s improving profitability, driven by better operating efficiencies and a favorable product mix. Biocon Biologics’ EBITDA margin is expected to remain stable, supported by its ability to manage costs and maintain pricing power. The company’s debt-to-EBITDA ratio is expected to remain moderate, providing it with the flexibility to pursue growth opportunities.
The stable outlook reflects S&P Global Ratings’ expectation that Biocon Biologics will maintain its strong business profile, driven by its established product portfolio and expanding global presence. The company’s significant investments in research and development are expected to yield new product launches, further enhancing its competitive position.
The upgrade is a significant milestone for Biocon Biologics, as it reflects the company’s ability to execute its strategy and deliver strong financial performance. The ‘BB+’ rating will provide the company with better access to capital markets, enabling it to pursue its growth plans and expand its global footprint. Biocon Biologics’ strong ratings will also enhance its credibility with customers, partners, and investors, further solidifying its position as a leading player in the biosimilars market.
Overall, the rating upgrade by S&P Global Ratings is a testament to Biocon Biologics’ strong fundamentals and growth prospects. The company’s commitment to innovation, quality, and customer satisfaction has enabled it to establish a strong position in the industry, and the ‘BB+’ rating reflects its ability to maintain this position and pursue new opportunities for growth.
Hyderabad to Witness ‘Global Voices, One Vision’ International Health Dialogue 2026, Hosted by Apollo Hospitals
The 13th edition of the International Health Dialogue (IHD) will be hosted by Apollo Hospitals in Hyderabad on January 30 and 31, 2026. The event will bring together global leaders to discuss patient safety, healthcare innovation, and system-wide transformation. The theme of IHD 2026, “Global Voices. One Vision,” emphasizes the shared commitment to building resilient, patient-centric, and technology-enabled healthcare systems. The two-day program will focus on leadership-driven safety models, human-centered design, digital transformation, and excellence in hospital operations, patient experience, and clinical outcomes.
The event will feature four major conferences: the International Patient Safety Conference, Healthcare Operations & Patient Experience Conference, Transforming Healthcare with IT Conference, and CLINOVATE, which will focus on the future of laboratories and diagnostics in patient safety and clinical decision-making. Global policymakers, including ministers of health from Niger, Papua New Guinea, and the Republic of Congo, will participate in the conference, along with prominent international experts such as Dr. Jonathan Perlin and Dr. Carsten Engel.
The conference will also include innovative features such as Safe-A-Thon, a collaborative challenge to develop practical patient safety solutions, and the launch of THNX, India’s first digital health startup community. THNX will facilitate pitch sessions, funding opportunities, and investor interactions. The event is expected to reinforce India’s growing role as a hub for global healthcare thought leadership and innovation.
According to Dr. Sangita Reddy, Joint Managing Director of Apollo Hospitals Group, the International Health Dialogue has evolved into a dynamic global platform where clinicians, innovators, and policymakers come together to shape the future of healthcare. The Hyderabad edition of IHD 2026 will bring together the power of AI, data, and digital ecosystems with the timeless values of empathy and collaboration to make healthcare more predictive, sustainable, and inclusive. With plenary sessions, innovation showcases, and global networking forums, the event is expected to be a significant gathering of global healthcare leaders.
Sun Pharma receives green light for obesity treatment injection similar to Wegovy.
Sun Pharmaceutical Industries has received approval for a weight loss injection similar to Novo Nordisk’s Wegovy. The new treatment, called “SUN-144”, is a once-weekly injection that helps with weight management in adults with obesity or overweight with at least one weight-related condition. This approval marks a significant milestone for Sun Pharma, as it enters the growing market for anti-obesity treatments.
Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been highly successful in treating obesity, with sales exceeding $1 billion in 2022. SUN-144 is also a GLP-1 receptor agonist, which works by mimicking a natural hormone that helps regulate appetite and food intake. Clinical trials have shown that SUN-144 is effective in reducing body weight and improving glycemic control in patients with type 2 diabetes.
The approval of SUN-144 is expected to increase competition in the anti-obesity market, which is currently dominated by Novo Nordisk’s Wegovy and Saxenda. However, Sun Pharma’s entry into the market may also lead to increased accessibility and affordability of these treatments, which could benefit patients who struggle with obesity and related health conditions.
Sun Pharma’s SUN-144 has shown promising results in clinical trials, with significant weight loss and improvements in cardiovascular risk factors. The treatment has also been well-tolerated, with common side effects including nausea, vomiting, and diarrhea. As the global prevalence of obesity continues to rise, the demand for effective and safe treatments is increasing. Sun Pharma’s entry into the market is expected to help meet this demand and provide patients with more options for managing their weight and related health conditions.
The approval of SUN-144 is a significant achievement for Sun Pharma, which has been expanding its portfolio of specialty and generic products. The company has a strong presence in the pharmaceutical industry, with a global footprint and a wide range of products. With the launch of SUN-144, Sun Pharma is poised to become a major player in the anti-obesity market, which is expected to continue growing in the coming years. As the company prepares to launch SUN-144, it is likely to focus on educating healthcare professionals and patients about the benefits and risks of the treatment, as well as its potential to improve health outcomes for individuals with obesity and related conditions.
Lupin achieves top ESG rating from CDP for its efforts in addressing climate change and water security.
Lupin, a global pharmaceutical leader, has been recognized for its exceptional sustainability efforts, receiving the highest “A” leadership rating from the Climate Disclosure Project (CDP) for both Climate Change and Water Security. This prestigious recognition solidifies Lupin’s position among the world’s most sustainable and transparent companies. The double “A” rating reflects Lupin’s significant progress in mitigating climate risks, reducing carbon emissions, and ensuring responsible water management across its operations.
Compared to its previous ratings, Lupin has made substantial improvements, upgrading from “A-” in 2024 and “B” and “C” in 2023 for climate and water, respectively. This remarkable achievement demonstrates Lupin’s commitment to sustainability and its proactive initiatives to minimize its environmental impact. Ramesh Swaminathan, Executive Director and Global CFO, expressed pride in earning the double “A” rating, attributing it to the company’s innovative approaches, collaborative efforts, and transparent practices.
Lupin’s sustainability endeavors have also been recognized by S&P Global, which awarded the company an ESG score of 91 in 2025. This achievement places Lupin among an elite group of companies worldwide that have surpassed the 90-point threshold, demonstrating its best-in-class sustainability performance. The CDP’s strict framework has played a significant role in shaping and accelerating Lupin’s climate initiatives, driving ongoing progress and commitment to establishing new sustainability standards.
The recognition from CDP and S&P Global underscores Lupin’s dedication to generating lasting value for its communities and the planet. As a global pharma leader, Lupin is committed to reducing its environmental impact through innovation, collaboration, and transparency, setting a high standard for sustainability in the industry. With its exceptional achievements, Lupin continues to demonstrate its position as a responsible and sustainable business leader, driving positive change and promoting a more environmentally conscious future.
Zydus Lifesciences introduces India’s first biosimilar version of Nivolumab, a global breakthrough.
Zydus Lifesciences, a leading life sciences company, has launched the world’s first biosimilar of nivolumab in India under the brand name Tishtha. This milestone marks a significant expansion of patient access to cutting-edge cancer therapies, particularly in the field of Immuno-Oncology. Tishtha will be available in two dosage strengths, 100 mg and 40 mg, priced at ₹28,950 and ₹13,950, respectively, which is approximately one-fourth of the reference product. This competitive pricing aims to improve treatment affordability and reduce the financial burden of cancer treatment.
The launch of Tishtha reinforces Zydus Lifesciences’ commitment to patient-centric care, with a focus on providing timely access to affordable and advanced cancer care. The company aims to support patients throughout their treatment journey, ensuring consistency, affordability, and reach. The development and manufacturing of Tishtha in India ensures long-term supply reliability, enabling patients to continue therapy without disruption.
The introduction of Tishtha in India significantly broadens access to advanced Immuno-Oncology treatments, making high-quality biosimilar immunotherapies accessible to a wider patient population. This launch is a pivotal step in Zydus Lifesciences’ efforts to make innovative, affordable healthcare solutions available to patients. By providing a reliable and consistent supply of Tishtha, the company aims to reduce clinical risk and financial stress associated with treatment interruptions.
According to Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences, every patient deserves timely access to affordable and advanced cancer care. The company’s commitment to patient access and affordability is reflected in the pricing of Tishtha, which is designed to minimize drug wastage and optimize dosing. With the launch of Tishtha, Zydus Lifesciences continues to play a leading role in advancing patient-centric Immuno-Oncology care in India, providing patients with access to innovative and affordable treatment options.
India’s Path To Universal Health Care Outlined In Lancet Paper Ahead Of Budget 2026 – BW Healthcare World
A recent paper published in The Lancet has outlined a roadmap for India to achieve universal health care by 2030, with a focus on the upcoming Budget 2026. The paper, titled “India’s path to universal health coverage: a call to action,” highlights the country’s progress towards achieving universal health care and identifies key areas that require attention and investment.
The authors of the paper note that India has made significant strides in improving health outcomes in recent years, with a decline in infant and maternal mortality rates, and an increase in life expectancy. However, despite these gains, the country still faces significant health challenges, including a high burden of non-communicable diseases, inadequate healthcare infrastructure, and a shortage of healthcare professionals.
To address these challenges, the paper recommends that the Indian government increase its investment in healthcare to at least 2.5% of the country’s GDP by 2025, with a focus on strengthening primary healthcare, improving healthcare infrastructure, and enhancing the skills of healthcare professionals. The authors also emphasize the need for a more equitable and inclusive healthcare system, with a focus on reaching marginalized and vulnerable populations.
The paper identifies several key areas that require attention and investment in the upcoming Budget 2026, including:
- Strengthening primary healthcare: The authors recommend increasing investment in primary healthcare, including the expansion of health and wellness centers, and the deployment of more community health workers.
- Improving healthcare infrastructure: The paper highlights the need for significant investment in healthcare infrastructure, including the construction of new hospitals, the upgrading of existing facilities, and the procurement of medical equipment.
- Enhancing the skills of healthcare professionals: The authors recommend increasing investment in the training and development of healthcare professionals, including doctors, nurses, and community health workers.
- Expanding health insurance coverage: The paper emphasizes the need to expand health insurance coverage to all citizens, with a focus on marginalized and vulnerable populations.
Overall, the paper provides a comprehensive roadmap for India to achieve universal health care by 2030, with a focus on strengthening primary healthcare, improving healthcare infrastructure, and enhancing the skills of healthcare professionals. The authors emphasize the need for significant investment in healthcare in the upcoming Budget 2026, and highlight the importance of a more equitable and inclusive healthcare system that reaches all citizens, regardless of their income or social status.
Glenmark introduces emergency epinephrine injection – Drug Store News
Glenmark Pharmaceuticals has launched an epinephrine injection, which is the first FDA-approved generic version of Auvi-Q, according to a report by Drug Store News. The epinephrine injection, also known as epinephrine injection, USP, is a prescription medication used to treat life-threatening allergic reactions, including anaphylaxis.
The medication is available in a pre-filled syringe and is administered via intramuscular injection, typically in the middle of the outer thigh. It is designed to provide fast and effective relief from severe allergic reactions, which can be caused by a range of allergens, including food, insect stings, and latex.
The launch of the epinephrine injection by Glenmark is significant, as it provides patients with a more affordable alternative to branded products. The list price of Glenmark’s epinephrine injection is expected to be lower than that of Auvi-Q, making it a more accessible option for patients who require this life-saving medication.
Glenmark’s epinephrine injection has been approved by the FDA in two doses: 0.3mg and 0.15mg. The 0.3mg dose is intended for patients who weigh 30kg or more, while the 0.15mg dose is intended for patients who weigh between 15kg and 30kg. The medication is available in a carton of two auto-injectors, each containing a single dose of epinephrine.
The launch of Glenmark’s epinephrine injection is an important development for patients who are at risk of anaphylaxis. Anaphylaxis is a severe and potentially life-threatening allergic reaction that requires immediate medical attention. Symptoms of anaphylaxis can include difficulty breathing, rapid heartbeat, and a drop in blood pressure. If left untreated, anaphylaxis can lead to serious health consequences, including death.
Glenmark’s epinephrine injection provides patients with a reliable and effective treatment option for anaphylaxis. The medication has undergone rigorous testing and has been shown to be safe and effective in clinical trials. With its launch, Glenmark is helping to expand access to this critical medication, making it more widely available to patients who need it.
Overall, the launch of Glenmark’s epinephrine injection is a significant development in the treatment of anaphylaxis. The medication provides patients with a fast and effective treatment option for severe allergic reactions, and its availability is expected to improve health outcomes for patients who are at risk of anaphylaxis.
Several major Indian pharmaceutical companies, including Sun Pharma, Cipla, Zydus, and Graviti, have issued recalls for certain medications in the United States market.
Several major pharmaceutical companies, including Sun Pharma, Cipla, Zydus, and Graviti Pharmaceuticals, are recalling various products in the US due to manufacturing issues, according to recent US FDA enforcement reports. The recalls are primarily related to problems with impurities, quality control, and production processes.
Sun Pharma is recalling over 24,000 bottles of Fluocinolone Acetonide topical solution and Clindamycin Phosphate topical solution due to out-of-specification results for impurities and assay. Cipla is recalling more than 15,000 syringes of Lanreotide Injection, used to treat a rare hormonal condition, due to production issues at its Greek manufacturing partner, Pharmathen. The production of Lanreotide has been temporarily paused to address quality concerns, resulting in limited supply.
Additionally, Cipla is recalling over 92,000 tubes of Diclofenac Sodium Topical Gel due to failed pH specifications. Graviti Pharmaceuticals is recalling over 4,000 bottles of Furosemide Tablets due to the presence of a foreign substance. Zydus Pharmaceuticals is recalling over 22,000 bottles of Icosapent Ethyl capsules due to oxidation caused by leakage, which may lead to inconsistent therapeutic effects and increased gastrointestinal side effects.
These recalls highlight the importance of quality control and manufacturing standards in the pharmaceutical industry. The FDA’s enforcement actions aim to ensure that products meet strict safety and efficacy standards to protect public health. The recalls may result in temporary shortages of these products, and patients are advised to consult their healthcare providers for alternative treatments.
The recalls also underscore the need for pharmaceutical companies to maintain robust quality control systems and adhere to good manufacturing practices (GMPs) to prevent such issues. The companies involved are taking corrective actions to address the problems and prevent future occurrences. The FDA will continue to monitor the situation and take further action if necessary to ensure the safety and efficacy of pharmaceutical products in the US market.
According to Apollo doctor, adopting three key lifestyle modifications can significantly safeguard cardiovascular well-being and reduce the risk of developing high blood pressure naturally.
High blood pressure, or hypertension, is a significant risk factor for cardiovascular disease, which is the leading cause of death worldwide. According to the World Health Organization (WHO), approximately 1.13 billion people globally suffer from hypertension, and this number is expected to increase to 1.5 billion by 2025. In an effort to mitigate this risk, a doctor from Apollo Hospital has recommended three essential lifestyle changes to protect heart health and naturally lower the risk of high blood pressure.
Firstly, the doctor emphasizes the importance of maintaining a healthy diet. A well-balanced diet rich in fruits, vegetables, whole grains, and lean proteins can help regulate blood pressure. Specifically, the doctor recommends consuming foods that are high in potassium, such as bananas, leafy greens, and sweet potatoes, as potassium helps to lower blood pressure by balancing out the effects of sodium in the body. Additionally, reducing sodium intake and limiting the consumption of processed and packaged foods is crucial in maintaining healthy blood pressure levels.
Secondly, regular physical activity is vital for heart health. Engaging in at least 150 minutes of moderate-intensity aerobic exercise, such as brisk walking, cycling, or swimming, or 75 minutes of vigorous-intensity aerobic exercise, such as running or HIIT (High-Intensity Interval Training), per week can significantly lower blood pressure. The doctor also recommends incorporating strength training exercises into one’s routine, as this can help improve overall cardiovascular health and reduce the risk of hypertension.
Lastly, managing stress is essential for maintaining healthy blood pressure levels. Chronic stress can lead to increased blood pressure, and the doctor recommends practicing stress-reducing techniques such as meditation, yoga, or deep breathing exercises. Getting adequate sleep, ideally 7-8 hours per night, is also crucial in regulating blood pressure and overall cardiovascular health.
In conclusion, making these three lifestyle changes can significantly reduce the risk of high blood pressure and promote overall heart health. By adopting a balanced diet, engaging in regular physical activity, and managing stress, individuals can naturally lower their blood pressure and reduce their risk of cardiovascular disease. The doctor emphasizes that these changes are simple yet effective and can be incorporated into one’s daily routine with minimal effort. By taking control of one’s lifestyle, individuals can take a proactive approach to protecting their heart health and reducing their risk of hypertension.
Lupin Achieves Prestigious CDP Double ‘A’ Rating for Excellence in Climate Change Mitigation and Water Stewardship
Lupin, a global pharmaceutical company, has achieved a significant milestone in its sustainability journey by earning a double ‘A’ rating from CDP (formerly known as the Carbon Disclosure Project) for its leadership in climate action and water security. This prestigious rating recognizes Lupin’s efforts to reduce its environmental impact and mitigate the risks associated with climate change and water scarcity.
CDP is a non-profit organization that assesses companies’ environmental performance and transparency. The double ‘A’ rating is the highest rating given by CDP, and it indicates that Lupin has demonstrated exceptional leadership and commitment to environmental stewardship. Lupin is one of only a few companies globally to achieve this rating, and it is a testament to the company’s dedication to sustainability.
Lupin’s climate action efforts have focused on reducing greenhouse gas emissions, transitioning to renewable energy sources, and implementing energy-efficient technologies. The company has set ambitious targets to reduce its carbon footprint, including a goal to become carbon neutral by 2050. Lupin has also implemented various initiatives to promote sustainable practices throughout its supply chain, including working with suppliers to reduce their environmental impact.
In addition to its climate action efforts, Lupin has also demonstrated leadership in water security. The company has implemented water conservation measures across its operations, including rainwater harvesting and wastewater treatment. Lupin has also engaged with local communities to promote water conservation and support watershed development projects.
The double ‘A’ rating from CDP is a significant achievement for Lupin, and it reflects the company’s commitment to sustainability and environmental responsibility. Lupin’s leadership in climate action and water security will not only reduce its environmental impact but also contribute to the well-being of local communities and the planet as a whole. The company’s sustainability efforts are aligned with the United Nations’ Sustainable Development Goals (SDGs), and it is working to integrate the SDGs into its business strategy.
Overall, Lupin’s double ‘A’ rating from CDP is a testament to the company’s dedication to sustainability and environmental stewardship. The company’s efforts to reduce its environmental impact and promote sustainable practices will have a positive impact on the environment, local communities, and its business operations. As a responsible corporate citizen, Lupin is committed to continuing its sustainability journey and making a positive difference in the world.
Bengaluru to host Zydus Pinkathon after a 7-year hiatus
The Zydus Pinkathon, a prominent women’s running event, is set to return to Bengaluru on January 25, marking its eighth edition in the city after a seven-year hiatus. With an expected participation of over 5,000 women, the event aims to promote fitness and community engagement among women of all age groups and fitness levels. The event will feature various race categories, including 3 km, 5 km, and 10 km runs, as well as ultradistances of 50 km, 75 km, and 100 km, and a 100 km relay.
The Bengaluru edition is being supported by the Department of Youth Empowerment and Sports, Government of Karnataka, and has received institutional backing from the Sports Authority of India and Fit India. The event is designed to encourage women to adopt regular physical activity, particularly in a city like Bengaluru, which is known for its young, working population and high-pressure lifestyles.
Founded by Milind Soman in 2012, Pinkathon has positioned Bengaluru as a key city in its journey, citing the city’s strong running culture and growing focus on wellness. The event has become a significant part of the city’s fitness landscape, and its return is expected to be a major boost to the city’s running community.
The Zydus Pinkathon is part of the 2025-26 nationwide season, which will also include events in Hyderabad on February 15 and Delhi on March 8. The event’s organizers aim to use the platform to promote fitness-led community engagement and encourage women to prioritize their physical and mental well-being. With its diverse range of race categories and inclusive approach, the Zydus Pinkathon is expected to be a memorable and empowering experience for all participants. Overall, the return of the Zydus Pinkathon to Bengaluru is a significant development for the city’s fitness enthusiasts and a testament to the growing importance of women’s health and wellness in India.
Glenmark Pharmaceuticals Names Neha Jangale as New Head of Learning and Development
Glenmark Pharmaceuticals, a leading global pharmaceutical company, has announced the appointment of Neha Jangale as the Head of Learning and Development (L&D). This strategic move aims to further strengthen the company’s commitment to employee development and growth.
Neha Jangale, with her extensive experience in the field of human resources, will be responsible for designing and implementing comprehensive learning and development programs across the organization. Her primary focus will be on creating a culture of continuous learning, enabling employees to acquire new skills, and enhancing their overall performance.
In her new role, Neha will work closely with the leadership team to identify skill gaps and develop targeted training programs to address these gaps. She will also be responsible for creating a robust framework for leadership development, succession planning, and talent management. Her expertise will help in creating a learning ecosystem that supports the company’s business objectives and fosters a culture of innovation and excellence.
Neha’s appointment is a testament to Glenmark’s commitment to investing in its employees and creating a work environment that encourages growth and development. The company recognizes that its employees are its most valuable assets and is dedicated to providing them with the necessary tools and resources to succeed.
Glenmark Pharmaceuticals has a strong track record of developing and implementing innovative L&D programs. The company has a dedicated L&D team that works closely with various stakeholders to design and deliver programs that cater to the diverse needs of its employees. With Neha at the helm, the company is expected to take its L&D initiatives to the next level, focusing on creating a more agile, adaptable, and future-ready workforce.
The appointment of Neha Jangale as the Head of L&D is a significant step forward for Glenmark Pharmaceuticals. Under her leadership, the company is poised to create a learning culture that is aligned with its business strategy and supports the growth and development of its employees. As the pharmaceutical industry continues to evolve, Glenmark is well-positioned to stay ahead of the curve, driven by a talented and skilled workforce. With Neha’s expertise and passion for L&D, the company is expected to achieve its vision of becoming a leading global pharmaceutical company.
Delhi High Court Dismisses Alkem’s Bid to Trademark ‘A TO Z’
The Delhi High Court has rejected a trademark claim by Alkem Laboratories, a pharmaceutical company, over the use of the term “A TO Z” for its products. The court ruled that alphabets are public property and cannot be monopolized by a single entity.
Alkem Laboratories had filed a lawsuit against another pharmaceutical company, Unichem Laboratories, alleging that Unichem’s use of the term “A TO Z” for its products infringed on Alkem’s trademark. Alkem claimed that it had been using the term “A TO Z” for its products since 1972 and had acquired a reputation and goodwill in the market.
However, the court rejected Alkem’s claim, stating that alphabets are public property and cannot be trademarked. The court observed that the term “A TO Z” is a common phrase used to denote a comprehensive range of products or services, and its use by Unichem did not infringe on Alkem’s trademark.
The court also noted that Alkem had not provided sufficient evidence to prove that its use of the term “A TO Z” had acquired a distinctive character and was exclusively associated with its products. The court held that the term “A TO Z” is a descriptive phrase and not a distinctive trademark.
The judgment is significant as it sets a precedent for the use of common phrases and alphabets in trademarks. It emphasizes that companies cannot claim exclusive rights over public property, such as alphabets, and that trademark law is intended to protect distinctive signs and symbols that identify a particular business or product.
The court’s decision is also a victory for Unichem Laboratories, which can continue to use the term “A TO Z” for its products without fear of infringement. The judgment highlights the importance of ensuring that trademark claims are not used to stifle competition or restrict the use of common language.
In conclusion, the Delhi High Court’s rejection of Alkem’s trademark claim over the term “A TO Z” is a significant ruling that emphasizes the public nature of alphabets and common phrases. The judgment sets a precedent for the use of trademarks and highlights the importance of protecting distinctive signs and symbols that identify a particular business or product.
Lupin Earns Top CDP A Rating for Efforts in Combating Climate Change and Conserving Water
Lupin Limited, a global pharmaceutical major, has achieved a significant milestone in its sustainability efforts by receiving the highest ‘A’ leadership rating from the Climate Disclosure Project (CDP) for its exceptional performance in Climate Change and Water Security. This recognition is a testament to Lupin’s commitment to sustainability and transparency, placing the company among the world’s leading organizations that prioritize environmental stewardship.
Lupin’s double ‘A’ rating in Climate and Water demonstrates its proactive approach to mitigating climate risks, reducing carbon emissions, and ensuring responsible water management throughout its operations. This achievement represents a significant improvement from the company’s previous ratings, with a substantial enhancement from ‘A-‘ in 2024 and ‘B’ in 2023 for climate, and ‘C’ for water. This progress reflects Lupin’s dedication to continuous improvement and its efforts to establish new sustainability standards.
The company’s Executive Director, Ramesh Swaminathan, attributed this achievement to Lupin’s innovative approaches, collaborative efforts, and transparency. He emphasized that the CDP’s framework has helped shape and accelerate the company’s climate initiatives, driving ongoing progress. Lupin’s commitment to sustainability is also reflected in its S&P Global ESG score of 91 in 2025, which is a best-in-class global achievement. This score positions Lupin among a select group of companies worldwide that have surpassed the 90-point threshold, demonstrating its exceptional performance in environmental, social, and governance (ESG) aspects.
Lupin’s achievement is a significant milestone in the pharmaceutical industry, highlighting the company’s dedication to reducing its environmental impact while generating lasting value for its communities and the planet. By prioritizing sustainability and transparency, Lupin is setting a high standard for the industry and demonstrating its commitment to creating a better future for all stakeholders. Overall, Lupin’s double ‘A’ rating from CDP and its exceptional ESG score are a testament to the company’s leadership in sustainability and its efforts to make a positive impact on the environment.
US FDA Concludes Inspection at Zydus’ Ankleshwar Facility with Three Noted Observations.
The US Food and Drug Administration (USFDA) has completed an inspection at Zydus Cadila’s manufacturing facility in Ankleshwar, Gujarat, with three observations. The inspection was conducted from February 13 to February 17, 2023. Although the company has not provided detailed information about the observations, it has stated that they are not related to data integrity or repeat observations from previous inspections.
The Ankleshwar plant is a key manufacturing facility for Zydus Cadila, producing a range of pharmaceutical products, including injectables, oral solids, and topical formulations. The USFDA inspection is a critical step in ensuring compliance with regulatory requirements for products exported to the US market. The observations made by the USFDA are considered minor, and the company is expected to respond to them within a specified timeframe.
Zydus Cadila has a history of USFDA inspections at its various manufacturing facilities. In 2020, the company’s Moraiya facility received a warning letter from the USFDA, citing several observations related to quality control and manufacturing practices. However, the company has since taken corrective actions and has been working to improve its compliance with regulatory requirements.
The outcome of the recent inspection at the Ankleshwar plant is seen as a positive development for Zydus Cadila, as it indicates that the company is on the right track in terms of compliance with USFDA regulations. The company’s management has stated that it is committed to maintaining high standards of quality and compliance at all its manufacturing facilities.
The inspection outcome is also significant for the Indian pharmaceutical industry as a whole, as it demonstrates the country’s ability to produce high-quality pharmaceutical products that meet international regulatory standards. India is a major player in the global pharmaceutical industry, with many companies exporting products to the US and other countries.
In conclusion, the USFDA’s inspection at Zydus Cadila’s Ankleshwar plant with three observations is a positive development for the company and the Indian pharmaceutical industry. While the observations are minor, the company will need to respond to them promptly to ensure compliance with regulatory requirements. The inspection outcome highlights the importance of maintaining high standards of quality and compliance in the pharmaceutical industry, and Zydus Cadila’s commitment to these principles is expected to support its growth and success in the global market.
A recall has been issued for a batch of MS medication after it was found that the capsules were dissolving at a slower rate than expected.
A batch of a multiple sclerosis (MS) medication has been recalled due to a manufacturing issue that affects the dissolution of the capsules. The medication, called Copaxone, is a glatiramer acetate injection used to treat relapsing forms of MS. The recall was initiated by the manufacturer, Teva Pharmaceuticals, after it was discovered that some capsules may not be dissolving at the expected rate.
The issue was identified during routine testing, which revealed that some capsules were not meeting the required dissolution specifications. As a result, Teva Pharmaceuticals has recalled the affected batch, which was distributed in the UK and other countries. The company has stated that the recall is a precautionary measure to ensure the quality and efficacy of the medication.
The slow dissolution of the capsules may affect the release of the active ingredient, glatiramer acetate, which could potentially impact the medication’s effectiveness in managing MS symptoms. However, Teva Pharmaceuticals has emphasized that there is no evidence to suggest that the affected batch poses a safety risk to patients.
Patients who are currently taking Copaxone are advised to check their medication packaging to see if it is part of the recalled batch. The affected batch numbers and expiry dates can be found on the Medicines and Healthcare products Regulatory Agency (MHRA) website. If a patient has a recalled batch, they should contact their pharmacist or healthcare provider for advice on what to do next.
Teva Pharmaceuticals has assured patients that alternative supplies of Copaxone are available, and that they are working to rectify the issue as quickly as possible. The company has also stated that it is cooperating fully with regulatory authorities to resolve the issue.
The recall highlights the importance of quality control measures in the pharmaceutical industry. Regular testing and inspection of medications are crucial to ensuring that they meet the required standards of quality, safety, and efficacy. The MHRA has stated that it is monitoring the situation closely and will take further action if necessary to protect public health.
In the meantime, patients with MS are advised to continue taking their medication as prescribed, unless advised otherwise by their healthcare provider. If patients have any concerns or questions about the recall, they should contact their pharmacist or healthcare provider for guidance and support.
Lupin Achieves Top ESG Score from CDP for Efforts in Combating Climate Change and Ensuring Water Security – Reported by Chennai Patrika.
Lupin Limited, a global pharmaceutical major, has achieved a significant milestone in its sustainability efforts by receiving the highest ‘A’ leadership rating from the Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. This recognition solidifies Lupin’s position as a global leader in championing sustainability and transparency. The company’s double ‘A’ rating in Climate and Water is a testament to its commitment to mitigating climate risks, reducing carbon emissions, and ensuring responsible water management throughout its operations.
This achievement represents a substantial improvement from Lupin’s previous ratings, with the company moving from ‘A-‘ in 2024 to ‘A’ in 2025, and from ‘B’ in 2023 to ‘A’ in 2025 for climate and water, respectively. This significant year-over-year progress demonstrates Lupin’s dedication to sustainability and its proactive initiatives aimed at reducing its environmental impact.
Ramesh Swaminathan, Executive Director, Global CFO and Head of API Plus SBU at Lupin, expressed pride in the company’s achievement, stating that Lupin has advanced its efforts to reduce environmental impact through innovation, collaboration, and transparency. He also acknowledged the role of CDP’s strict framework in shaping and accelerating the company’s climate initiatives, fostering ongoing progress.
In addition to the CDP rating, Lupin has also achieved an S&P Global ESG score of 91 in 2025, a best-in-class global achievement that positions the company among a distinguished group of companies worldwide that have surpassed the 90-point threshold. This recognition demonstrates Lupin’s commitment to establishing new sustainability standards and generating lasting value for its communities and the planet. Overall, Lupin’s achievements in sustainability and environmental responsibility underscore its position as a responsible and forward-thinking global pharmaceutical leader.
Sun Pharma receives DCGI approval for generic version of Wegovy, plans March release ahead of Semaglutide patent expiration.
Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to launch a generic version of Novo Nordisk’s Wegovy, a medication used to treat obesity. The approval comes as the patent for the active ingredient, semaglutide, is set to expire in March 2023.
Wegovy, which contains semaglutide, is an injectable glucagon-like peptide-1 (GLP-1) receptor agonist that helps with weight loss in adults with obesity. The medication has been shown to be effective in reducing body weight and improving glycemic control in patients with type 2 diabetes.
Sun Pharma’s generic version of Wegovy will be launched in India in March, coinciding with the patent expiry of semaglutide. The company has been working on developing a generic version of the medication for some time and has completed the necessary clinical trials and regulatory requirements to obtain approval from the DCGI.
The launch of Sun Pharma’s generic Wegovy is expected to increase access to this medication for patients in India, where obesity is a growing health concern. According to the World Health Organization (WHO), India has one of the highest rates of obesity in the world, with over 30% of the population classified as obese.
The generic version of Wegovy is also expected to be more affordable than the branded version, making it more accessible to patients who may not have been able to afford the medication otherwise. Sun Pharma’s entry into the market is likely to increase competition and drive down prices, benefiting patients and healthcare systems.
Novo Nordisk’s Wegovy has been a blockbuster medication, with sales of over $1 billion in 2022. The patent expiry of semaglutide is expected to lead to a significant increase in the availability of generic versions of the medication, which could impact Novo Nordisk’s sales. However, the company has a strong pipeline of new medications and is expected to continue to be a major player in the pharmaceutical industry.
Overall, the approval of Sun Pharma’s generic Wegovy is a significant development for patients in India, who will now have access to an affordable and effective treatment option for obesity. The launch of the generic medication is also expected to increase competition in the market, driving down prices and benefiting healthcare systems.
Alkem Laboratories slapped with ₹2.35 crore GST demand notice and penalty by Additional Commissioner, as reported by scanx.trade
Alkem Laboratories, a prominent Indian pharmaceutical company, has received a Goods and Services Tax (GST) demand order from the Additional Commissioner, totaling ₹2.35 crore, along with a penalty. The order, which was issued on [date], has sparked concerns among the company’s stakeholders and has the potential to impact its financial performance.
The GST demand order pertains to the period between [date] and [date], during which the company allegedly failed to pay the required GST on certain transactions. The Additional Commissioner has calculated the total tax liability to be ₹2.35 crore, which includes both the principal amount and the applicable interest.
In addition to the tax demand, the company has also been slapped with a penalty for non-compliance with GST regulations. The penalty amount, which is a significant portion of the total demand, is intended to deter companies from evading taxes and to ensure that they adhere to the tax laws.
Alkem Laboratories has stated that it is reviewing the GST demand order and will take necessary actions to address the issue. The company may choose to appeal against the order, or it may opt to pay the demanded amount to avoid further litigation.
The GST demand order and penalty have significant implications for Alkem Laboratories. The company’s financial performance may be impacted, as it will need to provision for the payment of the tax demand and penalty. Additionally, the company’s reputation may be affected, as non-compliance with tax laws can damage a company’s credibility and trustworthiness.
The pharmaceutical industry is already facing significant challenges, including regulatory pressures, intense competition, and pricing pressures. The GST demand order and penalty will add to the company’s woes, making it even more challenging for Alkem Laboratories to navigate the complex regulatory landscape.
In conclusion, Alkem Laboratories has received a significant GST demand order with a penalty from the Additional Commissioner. The company is reviewing the order and will take necessary actions to address the issue. The demand order and penalty have significant implications for the company’s financial performance and reputation, and it remains to be seen how the company will navigate this challenge. The outcome of this case will be closely watched by the pharmaceutical industry, as it will set a precedent for other companies that may be facing similar GST-related issues.
Cipla Collaborates with ImmunoACT to Introduce CAR-T Cell Therapy for Blood Cancer Treatment in African Markets.
Cipla, a leading pharmaceutical company, has partnered with ImmunoACT, a biotech firm, to launch CAR-T cell therapy for the treatment of blood cancers in Africa. This collaboration aims to make this innovative and potentially life-saving treatment more accessible to patients in the region.
CAR-T cell therapy is a form of immunotherapy that involves extracting a patient’s T cells, genetically modifying them to recognize and attack cancer cells, and then reinfusing them back into the body. This treatment has shown remarkable success in treating certain types of blood cancers, including leukemia and lymphoma.
The partnership between Cipla and ImmunoACT will enable the development and commercialization of CAR-T cell therapy in Africa, where access to such treatments is currently limited. Cipla will leverage its extensive distribution network and manufacturing capabilities to support the launch of the therapy, while ImmunoACT will provide its expertise in CAR-T cell technology and clinical development.
The launch of CAR-T cell therapy in Africa is a significant milestone, as it has the potential to transform the treatment landscape for blood cancers in the region. Currently, many patients in Africa lack access to effective treatments for these diseases, resulting in poor outcomes and high mortality rates. The introduction of CAR-T cell therapy is expected to improve treatment options and outcomes for these patients.
The partnership also highlights the growing importance of collaboration between pharmaceutical companies, biotech firms, and healthcare providers in addressing the complex challenges of cancer treatment in Africa. By working together, these stakeholders can pool their resources, expertise, and knowledge to develop and deliver innovative treatments that can make a meaningful difference in the lives of patients.
In addition to improving treatment options, the launch of CAR-T cell therapy in Africa is also expected to drive awareness and education about blood cancers and the importance of early diagnosis and treatment. This, in turn, can help to reduce stigma and promote a better understanding of these diseases, ultimately leading to improved health outcomes for patients and their families.
Overall, the partnership between Cipla and ImmunoACT to launch CAR-T cell therapy in Africa represents a significant step forward in the fight against blood cancers in the region. By making this innovative treatment more accessible, the partners aim to improve treatment options, outcomes, and quality of life for patients, while also driving awareness and education about these diseases.
Delhi High Court Rejects Interim Injunction, Rules That Letters ‘A’ and ‘Z’ Are Not Exclusive Property.
The Delhi High Court has made a significant ruling in a trademark infringement case, stating that the use of letters “A” and “Z” cannot be monopolized by a single entity. The court refused an interim injunction sought by a company that claimed exclusive rights to the use of these letters in its brand name.
The plaintiff, AZ Tech, had filed a lawsuit against the defendant, Zee Entertainment, alleging that the latter’s use of the letters “A” and “Z” in its logo and branding was a violation of its trademark rights. AZ Tech claimed that it had been using the letters “A” and “Z” in its brand name since 2018 and had acquired a distinctive reputation in the market.
However, the court rejected AZ Tech’s argument, stating that the use of letters “A” and “Z” is not unique to the plaintiff and cannot be monopolized. The court observed that the letters “A” and “Z” are part of the alphabet and are commonly used in many words and brand names. The court also noted that the plaintiff’s trademark registration was not sufficient to establish exclusive rights over the letters “A” and “Z”.
The court’s decision is significant as it sets a precedent for future trademark cases involving the use of common letters and symbols. The ruling suggests that companies cannot claim exclusive rights over common elements of the alphabet, and that trademark protection is limited to distinctive and unique marks that are capable of distinguishing one company’s goods or services from those of another.
The court’s refusal of the interim injunction is also a victory for Zee Entertainment, which can continue to use its logo and branding without fear of infringement. The case highlights the importance of careful consideration and research in choosing a brand name and logo, to avoid potential trademark disputes. The ruling also underscores the need for companies to ensure that their trademarks are distinctive and unique, and not based on common elements that cannot be monopolized.
In conclusion, the Delhi High Court’s decision is a significant development in trademark law, emphasizing that common letters and symbols cannot be monopolized by a single entity. The ruling provides clarity and guidance for companies seeking to protect their brand names and logos, and highlights the importance of careful consideration and research in trademark selection.
Biocon Expects Robust Q3 Performance Fueled by Biosimilar Growth
Biocon, a leading biopharmaceutical company, is expected to have a strong third quarter in the fiscal year 2026 (Q3FY26). The company’s biosimilars segment is anticipated to drive this growth, with key products such as bStelara playing a significant role. Analysts predict substantial revenue growth, driven by the increasing adoption of biosimilars in emerging markets. The generics segment is also expected to contribute to the company’s growth, with new product launches in the pipeline.
This quarter’s results will be the first to reflect the consolidation of Biocon Biologics Limited (BBL), which is expected to have a positive impact on the company’s topline. Analysts estimate that the topline will surge by 18% due to the consolidation. The integration of BBL is expected to enhance Biocon’s biosimilars capabilities and increase its global footprint.
The biosimilars segment is expected to be a key driver of growth for Biocon, with products like bStelara, a biosimilar version of the monoclonal antibody Stelara, expected to contribute significantly to revenue. The company’s emerging market strategy is also expected to pay off, with increasing demand for biosimilars in these markets.
However, the generics segment is expected to face intense competition, which could impact the company’s growth prospects. Despite this, the segment is expected to show promise, with new product launches in the pipeline. The company’s focus on research and development is expected to yield new products and technologies, which will help drive growth in the long term.
Overall, Biocon is poised for a strong Q3FY26, driven by its biosimilars segment and emerging market traction. The consolidation of BBL is expected to have a positive impact on the company’s topline, and the generics segment is expected to show promise despite intense competition. With a strong pipeline of new products and a focus on research and development, Biocon is well-positioned for long-term growth and success. The company’s Q3FY26 results will be closely watched by investors and analysts, who will be looking for signs of continued growth and momentum.
Mankind Pharma launches digital smart classrooms initiative in Ghaziabad as part of its KindCare corporate social responsibility program.
Mankind Pharma, a leading Indian pharmaceutical company, has launched a digital smart classroom initiative in Ghaziabad as part of its corporate social responsibility (CSR) program, KindCare. The initiative aims to provide quality education to underprivileged students and bridge the digital divide in the region. The company has set up modern classrooms equipped with digital tools, such as smartboards, computers, and internet connectivity, to create an engaging and interactive learning experience.
The digital smart classrooms are designed to cater to the educational needs of students from marginalized communities, who often lack access to quality educational resources. The initiative is expected to benefit over 1,000 students in the first phase, with plans to expand to more schools and locations in the future. Mankind Pharma has partnered with local schools and NGOs to identify the most deserving students and provide them with access to these digital classrooms.
The KindCare program is a comprehensive CSR initiative launched by Mankind Pharma to address various social and environmental issues, including education, healthcare, and environmental sustainability. The program focuses on creating a positive impact on the community and promoting inclusive growth. Through the digital smart classroom initiative, Mankind Pharma aims to not only improve the quality of education but also prepare students for the digital age.
The company believes that education is a key driver of social mobility and economic growth, and that every child deserves access to quality education, regardless of their socio-economic background. By providing digital smart classrooms, Mankind Pharma is empowering students with the skills and knowledge required to succeed in an increasingly digital world. The initiative is also expected to have a positive impact on the local community, as it will help to create a more educated and skilled workforce, contributing to the region’s economic growth and development.
Mankind Pharma’s commitment to CSR is reflected in its efforts to make a positive impact on the community. The company’s digital smart classroom initiative is a testament to its dedication to creating a better future for underprivileged students and promoting inclusive growth. By leveraging technology and partnerships, Mankind Pharma is bridging the digital divide and empowering students to achieve their full potential. The initiative is a step towards creating a more equitable and sustainable future, where every child has access to quality education and opportunities to succeed.
Sun Pharma Sets Sights on $10 Billion Organon Takeover to Bolster US Presence
Sun Pharmaceutical Industries Ltd., India’s largest drug manufacturer, is considering a monumental acquisition of Organon, a US-based company specializing in women’s health and biosimilars. The potential deal, valued at $10 billion, is being led by the company’s founder, Dilip Shanghvi. If successful, this acquisition would be a significant milestone for Sun Pharma, enabling the company to expand its presence in the lucrative US market and accelerate its growth in the high-potential biosimilars sector.
The acquisition of Organon would provide Sun Pharma with a substantial boost in the US market, where the company has been seeking to increase its presence. Organon’s portfolio of women’s health products and biosimilars would complement Sun Pharma’s existing product line, enabling the company to offer a more comprehensive range of treatments to patients. Additionally, the deal would grant Sun Pharma access to Organon’s established distribution network and sales infrastructure in the US, facilitating the company’s ability to reach a broader customer base.
The biosimilars sector is a high-growth area, with increasing demand for affordable alternatives to branded biologic medications. By acquiring Organon, Sun Pharma would gain a significant foothold in this market, enabling the company to capitalize on the growing demand for biosimilars. The deal would also provide Sun Pharma with the opportunity to leverage Organon’s expertise in developing and commercializing biosimilars, further enhancing the company’s capabilities in this area.
The potential acquisition of Organon is a testament to Sun Pharma’s ambition to become a leading global pharmaceutical player. Under the leadership of Dilip Shanghvi, the company has been actively pursuing strategic acquisitions and partnerships to drive growth and expansion. The acquisition of Organon would be a major milestone in this journey, marking a significant step towards establishing Sun Pharma as a major player in the global pharmaceutical industry.
Overall, the potential acquisition of Organon by Sun Pharma is a significant development in the pharmaceutical industry, with far-reaching implications for the company’s growth and expansion. If successful, the deal would enable Sun Pharma to establish a strong presence in the US market, accelerate its growth in the biosimilars sector, and cement its position as a leading global pharmaceutical player.
Mankind Pharma launches cutting-edge digital classrooms, bolstering community-centric education through KindCare initiative, as reported by India Education Diary.
Mankind Pharma, a leading pharmaceutical company, has launched digital smart classrooms as part of its KindCare initiative, aiming to revolutionize community-first education in India. The inauguration of these state-of-the-art classrooms marks a significant milestone in the company’s efforts to bridge the educational gap and provide quality learning opportunities to underprivileged students.
The digital smart classrooms are equipped with modern technology, including interactive whiteboards, projectors, and high-speed internet connectivity. This infrastructure will enable students to access a wide range of educational resources, including e-learning materials, online tutorials, and virtual labs. The classrooms will also facilitate interactive learning experiences, allowing students to engage with teachers and peers in a more effective and immersive manner.
The KindCare initiative is a testament to Mankind Pharma’s commitment to giving back to the community. The company has been actively involved in various corporate social responsibility (CSR) activities, focusing on education, healthcare, and environmental sustainability. By introducing digital smart classrooms, Mankind Pharma aims to empower students from disadvantaged backgrounds, providing them with the skills and knowledge necessary to succeed in an increasingly competitive world.
The digital smart classrooms will cater to students from government schools and underprivileged communities, offering them access to quality education and resources that they may not have otherwise had. The initiative will also provide training and support to teachers, enabling them to effectively integrate technology into their teaching methods and create a more engaging learning environment.
Mankind Pharma’s KindCare initiative has received praise from educators, policymakers, and community leaders, who recognize the potential of digital smart classrooms to transform the education landscape in India. The company’s efforts are aligned with the government’s Digital India initiative, which aims to promote digital literacy and connectivity across the country.
By investing in digital smart classrooms, Mankind Pharma is not only contributing to the educational development of underprivileged students but also promoting social equity and inclusion. The company’s commitment to community-first education reflects its vision of creating a more just and equitable society, where every individual has access to quality education and opportunities for growth and development. As Mankind Pharma continues to expand its KindCare initiative, it is likely to have a profound impact on the lives of thousands of students, empowering them to achieve their full potential and create a brighter future for themselves and their communities.
Organs of Tiruppur road accident victim declared brain dead, donated to save multiple lives at Tiruchi hospital
A team of doctors at Apollo Speciality Hospitals in Tiruchi, India, successfully harvested organs from a 45-year-old brain-dead road accident victim, saving the lives of several patients in need of transplants. The woman, a resident of Kannivadi village in Tiruppur district, was involved in a road accident on January 14 and was initially treated at Apollo Hospitals in Karur before being transferred to the Tiruchi facility. Despite receiving intensive care, she was declared brain dead by the medical team.
The woman’s family made the selfless decision to donate her organs, which were then retrieved through a series of coordinated surgical procedures. The harvested organs included her heart, liver, kidneys, and lungs. The liver and kidneys were transplanted into patients at Apollo Speciality Hospitals in Tiruchi, while the remaining organs were allocated to patients on the waiting list in accordance with the guidelines of the Tamil Nadu Transplant Authority (TRANSTAN).
The organ donation was carried out with the full support of the woman’s family, who were praised for their generosity and selflessness. The hospital officials and local authorities also played a key role in facilitating the donation process. The mortal remains of the organ donor were laid to rest with full honors, with the final rites conducted in the presence of officials from the District Collector of Tiruppur, including the Dharapuram Revenue Divisional Officer and Tahsildar Officer, as well as senior police officials and representatives from Apollo Speciality Hospitals.
This heartwarming story highlights the importance of organ donation and the impact it can have on saving lives. The selfless act of the woman’s family has given a new lease of life to several patients in need of transplants, and serves as an inspiration to others to consider organ donation. The successful transplantation of the organs is a testament to the expertise and dedication of the medical team at Apollo Speciality Hospitals, and the coordination and support of the local authorities and TRANSTAN.
US Sales of Revlimid Decline, Offset by Strong Domestic Market Growth
The Indian pharmaceutical industry is bracing for a challenging earnings season in Q3, with expectations of muted margins due to the loss of patent exclusivity for the blockbuster blood cancer drug Revlimid in the US. Revlimid, which has generated over $100 billion in global sales, has been a significant revenue and margin driver for Indian drugmakers such as Dr Reddy’s Laboratories, Cipla, Zydus Lifesciences, and Sun Pharma. However, with the patent expiry in January 2026, these companies will have to offload their remaining quotas, leading to a decline in sales.
Analysts expect a sector-wide decline in earnings before interest, taxes, depreciation, and amortization (Ebitda) margins by 150 basis points year-on-year, with companies such as Dr Reddy’s, Cipla, and Zydus Lifesciences likely to be affected. The decline in Revlimid sales will be a significant contributor to this margin pressure, with prices expected to erode sharply as players look to offload remaining quotas. Additionally, other factors such as increased generic price competition in the US market, higher research and development (R&D) expenses, and rising selling, general, and administrative (SG&A) costs will also weigh on margins.
Despite these challenges, analysts remain optimistic about the sector’s overall revenue growth, with expectations of 8-11% growth driven by steady domestic growth and traction in other markets. Domestic sales are projected to outpace the broader Indian pharmaceutical market’s 10.1% growth, with the chronic segment showing particular strength. Companies such as Lupin, Sun Pharma, and Cipla are expected to see growth driven by their innovative medicines portfolios and recent launches.
The US market, however, is expected to be a challenge, with overall US sales projected to decline by 4% quarter-on-quarter due to lower Revlimid sales. Excluding Revlimid, US generic sales are forecast to grow by 2% quarter-on-quarter, driven by volume expansion in existing products and the benefits from recent launches. Overall, while the loss of Revlimid patent exclusivity will be a significant challenge for Indian pharmaceutical companies, their domestic growth and innovative medicines portfolios are expected to provide some resilience and drive overall revenue growth.
A 14-year-old patient suffering from sickle cell disease undergoes hip replacement surgery at Apollo Hospital.
A 14-year-old girl from Nigeria, Grace Natasha Mwanasa, has undergone a successful total hip replacement surgery at Indraprastha Apollo Hospital in New Delhi. The surgery, led by renowned orthopaedic surgeon Dr. Yash Gulati, is one of the youngest cases of total hip arthroplasty in a patient with sickle cell disease. Grace was diagnosed with sickle cell disease in early childhood and had experienced recurring sickle cell crises, requiring multiple hospitalizations, ICU care, and blood transfusions.
In December 2025, Grace was admitted to Apollo Hospital with severe left hip pain, inability to walk, limping, and disturbed sleep due to constant pain. Evaluation revealed advanced avascular necrosis and complete destruction of the left femoral head, a known complication of sickle cell disease. Due to her severe pain, complete loss of hip movement, and significant functional disability, the medical team decided to proceed with total hip replacement.
The surgery required extensive preoperative planning, including an exchange blood transfusion to reduce HbS levels, which is a key component of sickle cell disease. The medical team also took precautions during anesthesia and surgery, including hydration, prevention of hypothermia, and meticulous bleeding control. The surgery was a success, and Grace is expected to recover and regain her mobility.
Dr. Gulati and his team’s expertise and careful planning were crucial in the success of the surgery. The case highlights the importance of timely and proper medical intervention in managing sickle cell disease and its complications. The surgery has given Grace a new lease on life, and she is expected to make a full recovery. The case also underscores the capabilities of Indian healthcare, with Indraprastha Apollo Hospital emerging as a hub for complex surgeries and treatments. The successful surgery has brought hope to patients suffering from sickle cell disease and other complex medical conditions, and has demonstrated the potential for effective treatment and management of these conditions with proper medical care.
Apollo Hospitals Managing Director denies rumors of a family feud, citing the demerger as a deliberate business strategy.
Apollo Hospitals Enterprise is undergoing a significant restructuring process, spinning off its pharmacy and digital health businesses into a separate entity called Apollo HealthCo. Managing Director Suneeta Reddy has clarified that this decision is driven by a desire to enhance shareholder value and is not related to family differences or changes in promoter dynamics. The restructuring is intended to create focused value for shareholders by allowing each business to operate with tailored strategies and metrics.
The hospital business and pharmacy-digital business have fundamental differences, including their nature, return profile, growth drivers, and workforce. The hospital business is focused on healthcare services, while the pharmacy-digital business is retail-focused. The spin-off will allow each business to operate independently and make decisions that are best for their respective industries.
Apollo HealthCo is projected to achieve 20% growth and is expected to be listed by FY27. The hospitals business is expected to grow at 18% over the next three years. The company is pivoting towards preventive healthcare, driven by the increasing burden of non-communicable diseases in India. Key health challenges, such as genetic predisposition to cardiac problems, rising cancer incidences, and India’s large diabetic population, are driving this strategic shift.
The company has ambitious expansion plans, including continued focus on metro cities, building a significant presence in tier-I cities, and exploring opportunities in tier-II cities. Apollo is also open to asset-light models and acquisitions, recognizing the significant healthcare infrastructure gap in India.
The company is investing in technology, including telemedicine and AI-powered clinical intelligence, to scale high-quality clinical offerings to larger populations. Looking ahead, Apollo is preparing to serve diverse demographic cohorts, from the growing geriatric population to millennials and Gen Z, each requiring tailored healthcare approaches encompassing preventive health, lifestyle interventions, and nutraceuticals. The restructuring and expansion plans are intended to position Apollo for long-term success and growth in the healthcare industry.
The Delhi High Court has granted permission to Zydus to market a more affordable biosimilar version of the cancer medication Nivolumab, citing public interest.
The Delhi High Court has given a significant ruling in favor of Zydus, a pharmaceutical company, allowing it to sell a biosimilar version of the cancer drug Nivolumab at a lower price. Nivolumab, marketed under the brand name Opdivo by Bristol Myers Squibb, is a monoclonal antibody used to treat various types of cancer, including melanoma, lung cancer, and kidney cancer. The court’s decision is expected to make the life-saving drug more accessible to patients in India.
Zydus had launched its biosimilar version of Nivolumab, called Itolizumab, in India, which is priced significantly lower than the original drug. However, Bristol Myers Squibb had approached the court, seeking an injunction to stop Zydus from selling the biosimilar, claiming that it infringed on their patent. The court, after hearing the arguments, ruled in favor of Zydus, stating that the company can continue to sell its biosimilar version of Nivolumab in the public interest.
The court’s decision is based on the fact that Nivolumab is a life-saving drug, and its high price makes it inaccessible to many patients in India. The court observed that the price of the original drug is exorbitant, and the biosimilar version launched by Zydus is priced at a significantly lower rate, making it more affordable for patients. The court also noted that Zydus has invested significant resources in developing the biosimilar and has obtained all necessary regulatory approvals.
The ruling is a significant win for patients in India, who will now have access to a more affordable version of the life-saving drug. The decision is also expected to have a positive impact on the Indian pharmaceutical industry, as it will encourage other companies to develop and launch biosimilars of expensive drugs, making them more accessible to patients.
The court’s decision is in line with the government’s efforts to make healthcare more affordable and accessible to all. The government has been promoting the use of biosimilars and generic drugs to reduce the cost of healthcare and make life-saving drugs more accessible to patients. The ruling is also expected to set a precedent for future cases, where pharmaceutical companies may approach the court to stop the sale of biosimilars, citing patent infringement. Overall, the court’s decision is a significant step towards making healthcare more affordable and accessible to all in India.
Piramal Pharma Enhances Its Global Sustainability Rating in Recent Corporate Assessment.
Piramal Pharma, a leading global pharmaceutical company, has achieved a significant improvement in its score on the Global Corporate Sustainability Assessment (CSA) conducted by S&P Global. The CSA is a widely recognized benchmark for assessing a company’s sustainability performance, evaluating factors such as environmental, social, and governance (ESG) practices.
In the latest assessment, Piramal Pharma’s score has increased by 13 points, reaching a total of 73 out of 100. This improvement reflects the company’s ongoing efforts to integrate sustainability into its business strategy and operations. The CSA assessment is based on a comprehensive evaluation of a company’s sustainability practices, including climate change, human rights, labor practices, and corporate governance.
The significant improvement in Piramal Pharma’s score can be attributed to its focused efforts on reducing its environmental footprint, enhancing its governance practices, and promoting social responsibility. Some of the key initiatives that contributed to this improvement include:
- Renewable energy: Piramal Pharma has increased its use of renewable energy sources, such as solar and wind power, to reduce its dependence on fossil fuels and lower its carbon emissions.
- Water conservation: The company has implemented water-saving measures and efficient wastewater management systems to minimize its water footprint.
- Waste reduction: Piramal Pharma has implemented a waste reduction program, which includes recycling and composting, to minimize waste disposal and reduce its environmental impact.
- Corporate governance: The company has strengthened its corporate governance practices, including board composition, executive compensation, and auditing practices.
- Social responsibility: Piramal Pharma has continued to invest in social responsibility initiatives, such as education, healthcare, and community development programs, to promote positive social impact.
The improved score on the Global Corporate Sustainability Assessment reflects Piramal Pharma’s commitment to sustainability and its efforts to create long-term value for its stakeholders. The company’s focus on sustainability is aligned with its mission to improve the quality of life for patients and communities worldwide. By integrating sustainability into its business strategy, Piramal Pharma aims to minimize its environmental footprint, promote social responsibility, and ensure long-term success.
Overall, Piramal Pharma’s achievement on the Global Corporate Sustainability Assessment demonstrates its dedication to sustainability and its commitment to creating a positive impact on the environment, society, and the economy. The company’s improved score serves as a testament to its efforts to balance business growth with social and environmental responsibility, making it a leader in the pharmaceutical industry.
Aurobindo Pharma Acquires Khandelwal Labs’ Non-Cancer Portfolio for ₹325 Crore.
Aurobindo Pharma, a leading Indian pharmaceutical company, has acquired the non-oncology business of Khandelwal Laboratories for ₹325 crore. The acquisition is a strategic move by Aurobindo Pharma to expand its product portfolio and strengthen its position in the domestic market.
Khandelwal Laboratories is a Mumbai-based pharmaceutical company that operates in the areas of oncology and non-oncology. The company has a strong product portfolio in the non-oncology segment, with a focus on therapeutic areas such as neurology, cardiology, and gastroenterology. The non-oncology business of Khandelwal Laboratories includes a range of products, including tablets, capsules, and injectables.
The acquisition of Khandelwal Laboratories’ non-oncology business will add over 50 products to Aurobindo Pharma’s portfolio, including some well-established brands. The products will be marketed and distributed by Aurobindo Pharma’s existing sales team, which has a strong presence in the domestic market. The acquisition is expected to be completed in the next few months, subject to regulatory approvals.
Aurobindo Pharma has stated that the acquisition is in line with its strategy to expand its product portfolio and increase its presence in the domestic market. The company has been looking to strengthen its position in the Indian market, where it faces intense competition from other pharmaceutical companies. The acquisition of Khandelwal Laboratories’ non-oncology business is expected to help Aurobindo Pharma achieve this objective.
The acquisition is also expected to be beneficial for Khandelwal Laboratories, as it will allow the company to focus on its oncology business. Khandelwal Laboratories has a strong presence in the oncology segment, and the company is expected to use the proceeds from the sale to invest in its oncology business.
The deal is valued at ₹325 crore, which is a significant amount for a pharmaceutical company of Khandelwal Laboratories’ size. The acquisition price includes the cost of acquiring the non-oncology business, including the products, manufacturing facilities, and marketing rights. Aurobindo Pharma has stated that the acquisition will be funded through a combination of internal accruals and debt.
Overall, the acquisition of Khandelwal Laboratories’ non-oncology business by Aurobindo Pharma is a significant development in the Indian pharmaceutical industry. The deal is expected to strengthen Aurobindo Pharma’s position in the domestic market and provide the company with a strong portfolio of products in the non-oncology segment.
Lupin partners with Gan & Lee to bring fortnightly GLP-1 treatment to India through exclusive licensing deal.
Lupin Limited, a global pharmaceutical company, has entered into an exclusive agreement with Gan&Lee Pharmaceuticals of China to commercialize Bofanglutide, a novel GLP-1 receptor agonist, in India. Bofanglutide is a fortnightly treatment for type 2 diabetes and weight management in overweight and obese adults, offering a reduced injection frequency compared to existing weekly GLP-1 therapies. Clinical data shows that the drug delivers comparable or better weight loss and glycaemic control outcomes, with a safety and tolerability profile consistent with the GLP-1 class.
The agreement strengthens Lupin’s metabolic health portfolio and marks its entry into the obesity treatment segment. India faces a significant burden of metabolic diseases, with an estimated 90 million adults living with diabetes and 50 million classified as obese. The convenience of a fortnightly dosing regimen may improve treatment adherence for patients requiring long-term therapy. Lupin’s Managing Director, Nilesh Gupta, commented that the agreement reflects the company’s commitment to expanding access to innovative therapies for chronic metabolic conditions.
The partnership also aligns with Gan&Lee Pharmaceuticals’ strategy to expand globally and bring its innovations to new markets. The company is a leading insulin manufacturer in China and has received regulatory approvals in multiple international markets. Lupin Limited, headquartered in Mumbai, operates in over 100 markets worldwide, with a strong presence in India and the United States. The company manufactures a range of products, including branded and generic formulations, complex generics, biotechnology products, and APIs, across 15 manufacturing sites and seven research centers globally.
The agreement is expected to benefit patients in India, where there is a growing need for effective treatments for metabolic diseases. With its strong presence in the Indian market, Lupin is well-positioned to commercialize Bofanglutide and make it accessible to patients who need it. The partnership between Lupin and Gan&Lee Pharmaceuticals is a significant development in the field of metabolic health and is expected to have a positive impact on the lives of millions of people in India and beyond.
Delhi High Court grants permission to Zydus to market Nivolumab biosimilar, a cancer treatment drug, in India.
The Delhi High Court has allowed Zydus Lifesciences to sell and market its biosimilar version of the anti-cancer drug nivolumab in India, despite a patent infringement suit filed by the innovator and patent holder, E.R. Squibb & Sons LLC. The court modified a previous order that had restrained the launch of Zydus’ biosimilar, citing public interest and the fact that the patent is set to expire on May 2, 2026. The bench of justices C. Hari Shankar and Om Prakash Shukla permitted continued sales of the biosimilar, directing Zydus to maintain detailed and audited records of its sales during this period so that Squibb can be compensated if it ultimately succeeds in the patent infringement suit.
Nivolumab is a life-saving cancer drug used to treat several types of cancer, including lung and head and neck cancer. The drug is expensive, with a vial costing between ₹21,500 to over ₹1,00,000, making affordability a concern. The dispute began when Squibb approached the Delhi High Court in 2024, alleging that Zydus was preparing to launch a biosimilar version of nivolumab before the expiry of its Indian patent. Squibb claimed that Zydus had developed a biosimilar, applied for regulatory approvals, and conducted clinical trials, indicating an imminent commercial launch during the patent term.
Zydus argued that its product did not infringe the patent and that it was developing a biosimilar in accordance with regulatory norms. The company also pointed to a pending post-grant opposition against Squibb’s patent filed by its group company. The court’s decision is a relief for Zydus and is expected to increase access to the life-saving drug for cancer patients in India. The court’s order also highlights the importance of balancing the rights of patent holders with the need to ensure access to affordable medicines, particularly in cases where the patent is nearing expiry.
The case is significant as it involves a biosimilar version of a critical cancer drug, and the court’s decision has implications for the pharmaceutical industry and patients in India. The court’s order is also a testament to the Indian judiciary’s commitment to ensuring that patent laws are balanced with the need to provide access to affordable medicines. The decision is expected to have a positive impact on the availability and affordability of cancer treatments in India, where the rate of cancer incidence is on the rise.
Alkem’s Renocia kit offers a cyclical nutritional supplement therapy designed to promote healthy hair growth.
Alkem Laboratories has launched a new product called Renocia cyclical therapy kit, a weekly nutritional supplementation regimen designed to support hair growth, strengthen hair follicles, and manage hair loss. The kit contains a set of vegetarian-sourced supplements, including vitamins, minerals, and amino acids, which are taken on specific days of the week. This structured protocol allows for better nutrient absorption and utilization.
According to Dr. Vikas Gupta, CEO of Alkem, nutritional supplementation plays a crucial role in hair health, but outcomes can vary depending on nutrient selection, absorption, and long-term adherence. The Renocia cyclical therapy kit offers a targeted approach that aligns with the body’s natural nutritional requirements throughout the week. By using only vegetarian-sourced ingredients, the company aims to make the product accessible to all sections of the Indian population.
The kit is available in a convenient wallet pack that contains supplements for four weeks, with clear instructions on which tablets to take on each day. The product is formulated separately for men and women to cater to their specific nutritional needs. Renocia cyclical therapy is a prescription product, and Alkem has a growing portfolio of products in the dermatology segment, including skin and hair care products.
The Renocia brand offers a range of hair care products, including hair revitalizing shampoo, conditioner, serum, and oral supplements. The launch of the cyclical therapy kit is a significant addition to the brand’s portfolio, providing a comprehensive solution for hair care. With its scientifically-designed regimen and vegetarian-sourced ingredients, the Renocia cyclical therapy kit is poised to make a positive impact on the hair care market in India.
Overall, the Renocia cyclical therapy kit is a innovative product that offers a structured approach to hair care, providing a convenient and effective solution for individuals looking to support hair growth and manage hair loss. With its focus on vegetarian-sourced ingredients and separate formulations for men and women, the product is likely to appeal to a wide range of consumers in India.
Mylan and Aurobindo Pharma must defend against allegations of colluding to fix prices for generic drugs.
A federal judge in Connecticut has rejected a request by Mylan Pharmaceuticals and Aurobindo Pharma USA to dismiss antitrust litigation against them. The judge ruled that a coalition of states has presented sufficient evidence to raise a genuine dispute about whether the companies conspired to fix drug prices. This decision allows the litigation to proceed against Mylan and Aurobindo, as well as 24 other pharmaceutical companies.
The antitrust litigation alleges that the pharmaceutical companies engaged in a conspiracy to fix prices, which is a violation of federal and state antitrust laws. The coalition of states, which is leading the litigation, claims that the companies’ alleged conspiracy has resulted in higher drug prices for consumers.
The judge’s decision is a significant setback for Mylan and Aurobindo, which had sought to have the litigation dismissed. The companies had argued that the states lacked sufficient evidence to support their claims, but the judge disagreed. The decision means that the litigation will continue, and the companies will be required to defend themselves against the allegations.
The litigation is part of a larger effort by states and federal authorities to crack down on alleged anticompetitive practices in the pharmaceutical industry. The industry has faced numerous lawsuits and investigations in recent years, and several companies have already settled allegations of price-fixing and other anticompetitive behaviors.
The judge’s decision is a victory for the coalition of states, which is seeking to hold the pharmaceutical companies accountable for their alleged actions. The litigation is likely to continue for several years, and the outcome is uncertain. However, the decision to allow the litigation to proceed is a significant step forward for the states and consumers who are seeking relief from high drug prices.
The case is being closely watched by the pharmaceutical industry and legal experts, who are interested in the potential implications of the litigation. A victory for the states could result in significant changes to the way pharmaceutical companies operate, and could lead to lower drug prices for consumers.
Biocon Biologics enhances its cancer treatment offerings with the introduction of three key biosimilar products.
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Limited, has announced plans to expand its oncology portfolio with the introduction of three new biosimilar candidates. The new additions include biosimilar versions of Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab, which are used to treat various types of cancer. With these new additions, Biocon Biologics will offer one of the broadest oncology biosimilar portfolios in the industry, addressing some of the world’s highest-revenue biologics that are expected to lose exclusivity over the next five years.
The company’s oncology portfolio represents a market opportunity exceeding $75 billion, accounting for nearly 35% of the global oncology pharmaceutical market. Biocon Limited has also announced plans to integrate Biocon Biologics as a wholly owned subsidiary, which is expected to simplify the corporate structure, enhance global commercial leverage, and strengthen Biocon’s leadership across diabetes, oncology, and immunology.
The integration, which is targeted to be completed by March 31, 2026, subject to regulatory approvals, will enable Biocon to offer biosimilar insulins alongside complex peptide generics, addressing the full continuum of diabetes care. Biocon Biologics’ CEO and Managing Director, Shreehas Tambe, commented that the integration will significantly enhance the company’s ability to deliver high-quality, affordable medicines at scale.
Biocon Biologics is a fully integrated global biosimilars company that serves over 6.3 million patients across 120 countries, providing high-quality biosimilars at affordable costs. The company has commercialized 10 biosimilars to date and has a pipeline of over 20 biosimilar assets spanning various therapeutic areas. Biocon Biologics is committed to advancing environmental, social, and governance priorities aligned with the United Nations Sustainable Development Goals.
The company’s expansion into the oncology market is expected to improve access to affordable cancer treatments worldwide. Biosimilars have been shown to be effective in reducing the cost of biologic treatments, making them more accessible to patients who may not have been able to afford them otherwise. With its expanded portfolio, Biocon Biologics is well-positioned to play a significant role in the global oncology market. The company’s commitment to delivering high-quality, affordable medicines is expected to have a positive impact on patients and healthcare systems worldwide.
The High Court has asked Novo Nordisk to respond to Natco’s request to cancel its patent.
The Delhi High Court has ordered Novo Nordisk, a Danish pharmaceutical company, to respond to a petition filed by Natco Pharma, a Hyderabad-based company, seeking to revoke the patent on the diabetes and anti-obesity drug semaglutide. The patent, which is set to expire in March, has been a subject of controversy, with Natco Pharma claiming that it lacks novelty and that Novo Nordisk is attempting to “evergreen” the patent to extend its exclusivity beyond the primary patent’s expiry.
Novo Nordisk has developed semaglutide and sells it under various brand names, including Wegovy, Rybelsus, and Ozempic, for the treatment of type-2 diabetes and weight loss. The company has regulatory approval to sell Ozempic in India. However, with the patent’s expiry looming, several generic companies, including Natco Pharma, are attempting to manufacture their own versions of the drug.
The Delhi High Court’s Justice Jyoti Singh has issued a notice to Novo Nordisk, directing the company to respond to Natco Pharma’s petition. The case has been listed for further hearing in February. The outcome of this case will have significant implications for the pharmaceutical industry, particularly in India, where there is a growing demand for affordable diabetes and obesity treatments.
Natco Pharma’s petition argues that Novo Nordisk’s patent on semaglutide is not novel and that the company is attempting to extend its exclusivity beyond the primary patent’s expiry. If the court rules in favor of Natco Pharma, it could pave the way for other generic companies to manufacture and sell their own versions of semaglutide, potentially increasing competition and reducing prices for the drug.
The case highlights the ongoing patent disputes in the pharmaceutical industry, particularly in India, where generic companies are increasingly challenging the patents of multinational pharmaceutical companies. The outcome of this case will be closely watched by the industry, as it could have significant implications for the availability and affordability of essential medicines in India and beyond.
Sun Pharmaceutical Industries suffers loss in trademark dispute as Bombay High Court rules EsiRaft and Raciraft do not bear deceptive similarities.
The Bombay High Court has ruled in favor of Eris Lifesciences, dismissing Sun Pharmaceutical’s claim that Eris’s medication “EsiRaft” infringed on Sun Pharma’s trademark for their medication “Raciraft”. The court found that the names “EsiRaft” and “Raciraft” are not deceptively similar, and therefore, Eris Lifesciences did not infringe on Sun Pharma’s trademark.
Sun Pharma had filed a lawsuit against Eris Lifesciences, alleging that the name “EsiRaft” was too similar to their own medication “Raciraft”, which could cause confusion among consumers. However, the Bombay High Court disagreed, stating that the names are distinct and not likely to cause confusion.
The court noted that the prefix “Esi” in EsiRaft is a well-known abbreviation for Eris Lifesciences, which is a well-established pharmaceutical company. In contrast, the prefix “Raci” in Raciraft is a unique identifier for Sun Pharma’s medication. The court also observed that the suffix “Raft” in both names is a common term used in the pharmaceutical industry to denote a type of medication.
The court’s decision is a significant win for Eris Lifesciences, as it allows the company to continue marketing and selling its medication “EsiRaft” without fear of trademark infringement. The ruling also sets a precedent for the pharmaceutical industry, establishing that minor similarities in medication names do not necessarily constitute trademark infringement.
The case highlights the importance of trademark law in the pharmaceutical industry, where companies invest heavily in developing and marketing their medications. The ruling demonstrates that courts will carefully consider the nuances of trademark law and the potential for consumer confusion when determining whether a trademark infringement has occurred.
In conclusion, the Bombay High Court’s decision in the case of Sun Pharma vs. Eris Lifesciences is a significant victory for Eris Lifesciences, allowing the company to continue marketing its medication “EsiRaft” without fear of trademark infringement. The ruling sets a precedent for the pharmaceutical industry and highlights the importance of careful consideration of trademark law in determining whether a trademark infringement has occurred.
PolyPeptide forms partnership with Lupin | Speciality Chemicals Magazine
PolyPeptide, a leading manufacturer of peptides, has formed a strategic alliance with Lupin Manufacturing Solutions. The partnership aims to establish a framework for long-term cooperation, focusing on integrated procurement and supply planning for select raw materials. This alliance will enable PolyPeptide to diversify its sourcing options for key materials, including metabolites, and create a more robust and flexible supply chain for peptide manufacturing.
The demand for peptides has been increasing, and this alliance will help PolyPeptide to better meet the growing needs of its customers. By collaborating with Lupin Manufacturing Solutions, PolyPeptide will be able to secure a stable supply of essential raw materials, reducing its dependence on a single supplier and minimizing potential risks.
This partnership is the second significant collaboration announced by PolyPeptide in recent times. The company has also signed a collaboration agreement with Lifecore Biomedical, a contract development and manufacturing organization (CDMO). The agreement combines PolyPeptide’s expertise in peptide manufacturing and development with Lifecore’s capabilities in formulation, fill-finish, and packaging.
The partnership with Lifecore Biomedical will provide US-based manufacturers of peptide drugs with an integrated, end-to-end solution. The collaboration will enable a seamless transition between drug substance and drug product, streamlining the manufacturing process and reducing costs. By offering a comprehensive solution, PolyPeptide and Lifecore Biomedical aim to become the preferred partners for companies developing peptide-based drugs.
The financial details of both alliances have not been disclosed. However, these partnerships demonstrate PolyPeptide’s commitment to enhancing its capabilities and expanding its reach in the peptide manufacturing market. By forming strategic alliances with other industry leaders, PolyPeptide is well-positioned to capitalize on the growing demand for peptides and maintain its position as a leading manufacturer in the industry.
The alliances with Lupin Manufacturing Solutions and Lifecore Biomedical will enable PolyPeptide to improve its supply chain, reduce costs, and offer a more comprehensive range of services to its customers. As the demand for peptides continues to increase, PolyPeptide’s strategic partnerships will play a crucial role in driving its growth and success in the market.
National Pharmaceutical Pricing Authority Caps Retail Price of Sun Pharma’s Gemcitabine Injections
The National Pharmaceutical Pricing Authority (NPPA) has set the retail price for Sun Pharma’s Gemcitabine injections. Gemcitabine is a chemotherapy medication used to treat various types of cancer, including pancreatic, breast, ovarian, and non-small cell lung cancer. The NPPA, which is responsible for regulating the prices of pharmaceutical products in India, has fixed the retail price of Sun Pharma’s Gemcitabine injections to ensure that the medication is affordable for patients.
The price fixation is a significant move, as it will help to make the life-saving medication more accessible to cancer patients in India. Gemcitabine is a critical component of cancer treatment, and its high cost has been a significant burden on patients and their families. The NPPA’s decision is expected to provide relief to patients who are struggling to afford the medication.
The retail price of Sun Pharma’s Gemcitabine injections has been fixed at a level that is significantly lower than the existing market price. This will result in significant savings for patients who are undergoing cancer treatment. The price reduction is expected to benefit thousands of patients who are dependent on Gemcitabine for their treatment.
The NPPA’s decision is in line with the government’s efforts to make healthcare more affordable and accessible to all. The authority has been working to regulate the prices of pharmaceutical products, including cancer medications, to ensure that they are affordable for patients. The price fixation of Gemcitabine is a significant step in this direction and is expected to have a positive impact on the healthcare sector.
The move is also expected to promote competition in the market, as other pharmaceutical companies may be forced to reduce their prices to remain competitive. This will ultimately benefit patients, who will have access to affordable and high-quality medication. The NPPA’s decision is a significant development in the pharmaceutical sector and is expected to have a positive impact on the healthcare industry as a whole.
Overall, the NPPA’s decision to fix the retail price of Sun Pharma’s Gemcitabine injections is a welcome move that will benefit cancer patients in India. The price reduction will make the medication more accessible and affordable, and will help to reduce the financial burden on patients and their families. The move is in line with the government’s efforts to make healthcare more affordable and accessible, and is expected to have a positive impact on the healthcare sector.
GCC will operate dialysis centers in Kolathur and Kondithope.
The Greater Chennai Corporation (GCC) will oversee and maintain two dialysis centers being constructed by the Chennai Metropolitan Development Authority (CMDA) in Kolathur and Kondithope. The centers will provide blood purification services, and the GCC has proposed covering the beneficiaries under the Chief Minister’s Comprehensive Health Insurance Scheme (CMCHIS). Until the scheme is formally approved, the GCC will bear the dialysis treatment costs, which will be operated by Apollo Hospitals.
The Kolathur center, located in the Thiru-Vi-Ka Nagar zone, will be a multi-story facility offering integrated services. The center will have an artificial limb center on the first floor, a physical training center on the second floor, a blood purification unit for dialysis procedures on the third floor, and patient amenities on the fourth floor. Similarly, the Kondithope facility, located in the Royapuram zone, will function as a comprehensive rehabilitation center with similar facilities.
The decision to establish these centers was made in a meeting chaired by CMDA Minister PK Sekarbabu in September. The meeting decided that while the CMDA would establish the facilities, the GCC would handle their operation and maintenance. The GCC’s joint commissioner (Health) and the North Chennai regional deputy commissioner were also present at the meeting.
The construction of these dialysis centers aims to provide accessible and affordable healthcare services to the residents of Chennai. The GCC’s decision to bear the treatment costs until the CMCHIS is approved ensures that the beneficiaries can receive the necessary treatment without any delays. The comprehensive rehabilitation centers will also provide a range of services, including artificial limb fitting, physical training, and patient amenities, making them a one-stop destination for patients requiring dialysis and rehabilitation services. Overall, the establishment of these centers is expected to improve the healthcare infrastructure in Chennai and provide better services to the residents.
Aurobindo Pharma Pushes Back Deadline to Purchase 26% Stake in Swarnaakshu Solar
Aurobindo Pharma has extended the timeline to acquire a 26% stake in Swarnaakshu Solar, a solar power company. The acquisition is part of Aurobindo Pharma’s strategy to diversify its business and invest in renewable energy.
The company had initially planned to complete the acquisition by a certain deadline, but it has now been extended due to various reasons. The extension of the timeline is expected to give Aurobindo Pharma more time to complete the necessary formalities and regulatory approvals.
Aurobindo Pharma is one of the leading pharmaceutical companies in India, and its decision to invest in Swarnaakshu Solar marks a significant departure from its core business. The company has been looking to diversify its portfolio and reduce its dependence on the pharmaceutical sector.
Swarnaakshu Solar is a solar power company that specializes in the development and operation of solar power plants. The company has a strong presence in the Indian renewable energy market and has developed several solar power projects across the country.
The acquisition of a 26% stake in Swarnaakshu Solar is expected to give Aurobindo Pharma a significant foothold in the renewable energy sector. The company plans to use the investment to expand its presence in the solar power market and to reduce its carbon footprint.
The extension of the timeline to acquire a stake in Swarnaakshu Solar is not expected to have a significant impact on Aurobindo Pharma’s financial performance in the short term. However, the investment is expected to provide long-term benefits to the company and help it to achieve its sustainability goals.
Aurobindo Pharma’s decision to invest in Swarnaakshu Solar is part of a larger trend of pharmaceutical companies diversifying their business and investing in renewable energy. The investment is expected to help the company to reduce its dependence on fossil fuels and to achieve its sustainability goals.
Overall, the extension of the timeline to acquire a stake in Swarnaakshu Solar is a positive development for Aurobindo Pharma and marks a significant step forward in the company’s strategy to diversify its business and invest in renewable energy. The investment is expected to provide long-term benefits to the company and help it to achieve its sustainability goals.
Delhi High Court bars Dr Reddy’s from producing VENUSIA sunscreens bearing the SUN logo.
The Delhi High Court has issued an interim order restraining Dr. Reddy’s Laboratories from manufacturing and selling its VENUSIA sunscreens with a label that includes the word “SUN”. The court’s decision comes in response to a lawsuit filed by Glenmark Pharmaceuticals, which claims that Dr. Reddy’s is infringing on its trademark rights.
Glenmark Pharmaceuticals had launched its own sunscreen product, SUNSTAR, in 2018, and had obtained a trademark registration for the mark “SUN” in relation to sunscreen products. The company claims that Dr. Reddy’s use of the word “SUN” on its VENUSIA sunscreens is likely to cause confusion among consumers and dilute the distinctiveness of Glenmark’s trademark.
The Delhi High Court has agreed with Glenmark’s arguments, observing that Dr. Reddy’s use of the word “SUN” on its products is likely to cause confusion among consumers, who may mistakenly believe that the VENUSIA sunscreens are connected to Glenmark’s SUNSTAR product. The court has therefore restrained Dr. Reddy’s from using the word “SUN” on its VENUSIA sunscreens, pending the outcome of the lawsuit.
The court’s order is a significant setback for Dr. Reddy’s, which had launched its VENUSIA sunscreens with the SUN label in an attempt to capitalize on the popularity of sunscreens in the Indian market. The company will now have to rebrand its products and remove the SUN label, which could result in significant losses and damage to its reputation.
The lawsuit highlights the importance of trademark protection in the pharmaceutical industry, where companies invest heavily in building their brands and trademarks. The Delhi High Court’s decision demonstrates that courts will take a strict view of trademark infringement, particularly in cases where there is a likelihood of confusion among consumers.
The case will now proceed to trial, where Glenmark will have to prove that Dr. Reddy’s use of the word “SUN” on its VENUSIA sunscreens constitutes trademark infringement. If the court ultimately rules in favor of Glenmark, Dr. Reddy’s could face significant damages and penalties for its alleged infringement. The case is being closely watched by the pharmaceutical industry, which is keen to see how the courts will interpret trademark laws in cases of alleged infringement.
Tragedy strikes in Bengaluru as 26-year-old Biocon staff member takes fatal leap from 5th floor of office building.
A 26-year-old employee of Biocon, a biopharmaceutical company, jumped to his death from the 5th floor of the company’s office building in Bengaluru, India. The incident occurred on a recent day, and the police are currently investigating the circumstances surrounding the death.
According to reports, the employee, whose identity has not been disclosed, was working in the research and development department of Biocon. He was a resident of Bengaluru and had been working with the company for several years. The police have stated that they are reviewing CCTV footage and speaking with colleagues and family members to determine the cause of the incident.
The incident has sent shockwaves through the company, with many colleagues and friends expressing their condolences on social media. Biocon has released a statement expressing its sadness and shock at the incident, and has offered support to the employee’s family.
The police have ruled out any foul play in the incident, and are treating it as a case of suicide. However, they are still investigating the circumstances that led to the employee’s death, including any potential work-related stress or personal issues.
This incident highlights the growing concern of mental health and stress in the corporate world, particularly in the tech and biotech industries. Many employees in these industries face high levels of stress and pressure to perform, which can take a toll on their mental health. Companies are increasingly recognizing the importance of providing support and resources to employees to manage stress and promote mental well-being.
Biocon has a reputation for being a supportive and employee-friendly company, with a range of initiatives and programs in place to promote employee well-being. However, this incident highlights the need for companies to do more to support employees who may be struggling with mental health issues.
The incident is also a reminder of the importance of seeking help and support when struggling with mental health issues. If you or someone you know is struggling with mental health issues, there are resources available to help. The National Institute of Mental Health and Neuro Sciences (NIMHANS) has a 24-hour helpline that provides support and counseling services. Additionally, many companies have employee assistance programs (EAPs) that provide confidential counseling and support services to employees.
India’s pharmaceutical sector faces a pivotal year of transformation: Adapting to change and embracing a shifting worldwide landscape | Hindustan Times
The Indian pharmaceutical industry has faced significant challenges in recent years, but 2022 has been a defining year for the sector. The industry has had to navigate disruptions caused by the COVID-19 pandemic, regulatory changes, and global trade tensions. Despite these challenges, Indian pharma has shown resilience and adaptability, and is now preparing for a new global order.
One of the major disruptions faced by the industry has been the pandemic, which has led to supply chain disruptions, lockdowns, and changes in demand patterns. However, Indian pharma companies have responded by investing in digital transformation, diversifying their product portfolios, and expanding their global footprint. The industry has also seen a significant increase in investments in research and development, with a focus on developing new and innovative products.
Regulatory changes have also been a major challenge for the industry. The Indian government has introduced several policies aimed at promoting the domestic pharmaceutical industry, including the Production Linked Incentive (PLI) scheme, which provides incentives to companies that invest in domestic manufacturing. The government has also introduced new regulations aimed at improving the quality of pharmaceutical products and reducing the risk of counterfeit medicines.
Despite these challenges, the Indian pharmaceutical industry has continued to grow, with exports increasing by over 20% in the past year. The industry has also seen a significant increase in foreign investments, with several global companies investing in Indian pharma companies. The industry is also expected to benefit from the government’s efforts to promote the development of a domestic pharmaceutical industry, including the establishment of pharmaceutical parks and clusters.
As the industry prepares for a new global order, it is likely to face new challenges and opportunities. The COVID-19 pandemic has accelerated the trend towards digitalization and online healthcare, and Indian pharma companies will need to invest in digital technologies to remain competitive. The industry will also need to navigate the changing global trade landscape, including the impact of Brexit and the US-China trade war.
Overall, 2022 has been a defining year for the Indian pharmaceutical industry, with the sector navigating significant disruptions and preparing for a new global order. The industry has shown resilience and adaptability, and is well-positioned to take advantage of new opportunities and challenges in the coming years. With the government’s support and the industry’s own efforts, Indian pharma is likely to continue to grow and thrive, and play an increasingly important role in the global pharmaceutical industry.
Indian pharma companies are working to develop new and innovative products, including vaccines, biologics, and gene therapies. The industry is also investing in emerging technologies such as artificial intelligence, blockchain, and the Internet of Things (IoT) to improve the quality and efficiency of its operations. As the industry looks to the future, it is clear that Indian pharma will play an increasingly important role in the global pharmaceutical industry, and will continue to be a major driver of economic growth and innovation in India.
Bombay High Court Denies Sun Pharma’s Request for Temporary Restraining Order Against Competitor EsiRaft, Allowing it to Continue Challenging RACIRAFT
The Bombay High Court has refused to grant an interim injunction to Sun Pharmaceutical Industries Limited, allowing Meghmani Lifesciences Limited to continue using the trademark “EsiRaft” for its pharmaceutical product. The court found that the mark is not deceptively similar to Sun Pharma’s “RACIRAFT” and that there is no likelihood of confusion between the two marks.
Sun Pharma had filed a trademark infringement and passing off suit against Meghmani Lifesciences, claiming that the use of “EsiRaft” infringed on its goodwill and was likely to cause confusion among consumers. However, the court held that the marks are visually and phonetically dissimilar and that the element “RAFT” is descriptive of the product’s characteristics and cannot be used to establish deceptive similarity.
The court also noted that the prefixes “RACI” and “ESI” are distinct and that Meghmani Lifesciences’ adoption of the mark was bona fide. The company had explained that “ESI” referred to “Enhanced System Improvement” and “Esophageal Symptom Index”. The court observed that the use of two-color combinations on the packaging was common in the trade and was insufficient to establish infringement.
The court applied the principles of trademark law, including the anti-dissection rule, the viewpoint of an average consumer with imperfect recollection, and the likelihood of confusion. It found that the competing marks are prima facie visually and phonetically dissimilar and will not create any confusion in the minds of consumers.
In dismissing Sun Pharma’s interim injunction plea, the court held that the company had failed to make out a prima facie case of trademark infringement or passing off. The court also vacated an earlier ex-parte ad-interim injunction that had restrained Meghmani Lifesciences from using the disputed mark. The decision allows Meghmani Lifesciences to continue using the “EsiRaft” mark for its product, which is used to treat heartburn and indigestion.
The case highlights the importance of careful consideration of trademark similarity and the need for companies to establish a strong case of infringement or passing off in order to obtain an interim injunction. The court’s decision is significant, as it allows Meghmani Lifesciences to continue marketing its product without interruption, while also protecting the rights of Sun Pharma to pursue its claims in the main suit.
The court’s observation that the get-up of the marks itself is different and the overall visual appearance of the rival products is dissimilar, is crucial in determining the likelihood of confusion. The decision also emphasizes the need for companies to ensure that their trademarks are distinctive and do not infringe on the rights of other companies.
In conclusion, the Bombay High Court’s decision in this case provides guidance on the principles of trademark law and the factors that are considered in determining the likelihood of confusion between two marks. The decision is a significant one, as it allows Meghmani Lifesciences to continue using the “EsiRaft” mark, while also protecting the rights of Sun Pharma to pursue its claims in the main suit.
Sun Pharma Wins Reprieve as CESTAT Sends Back Rs. 3.90 Crore Excise Demand for Re-Assessment Over EOU DTA Sales and Deemed Exports – Juris Hour
The Customs, Excise, and Service Tax Appellate Tribunal (CESTAT) has remanded a Rs. 3.90 crore excise demand against Sun Pharmaceutical Industries Ltd. regarding sales from an Export Oriented Unit (EOU) to a Domestic Tariff Area (DTA). The tribunal has directed the authorities to recalculate the deemed exports and the corresponding excise duty liability.
The dispute arose from the company’s sales from its EOU to its DTA unit, which were treated as deemed exports under the Export and Import Policy. The excise authorities demanded duty on these sales, claiming that they were not genuine exports. Sun Pharma argued that the sales were eligible for exemption under the exemption notification, as they were deemed exports.
The CESTAT observed that the excise authorities had not properly verified the deemed export benefits claimed by the company. The tribunal noted that the authorities had not considered the export proceeds realized by the company and had not verified the consumption of the goods in the DTA.
The CESTAT held that the excise authorities’ demand was not sustainable and remanded the matter to the original authority to recalculate the deemed exports and the corresponding excise duty liability. The tribunal directed the authorities to consider the export proceeds realized by the company and to verify the consumption of the goods in the DTA.
The CESTAT’s order is significant, as it clarifies the treatment of sales from an EOU to a DTA under the excise law. The order also highlights the importance of proper verification and calculation of deemed export benefits. The remand order will allow the authorities to re-examine the company’s claims and calculate the correct excise duty liability.
The case emphasizes the need for exporters to maintain accurate records and documentation to support their claims for deemed export benefits. It also underscores the importance of proper verification and calculation by the excise authorities to ensure that the correct excise duty liability is determined. The CESTAT’s order will provide guidance to other exporters and excise authorities in similar cases, ensuring consistency and clarity in the application of the excise law.
Experts from Apollo, Aster CMI, and Fortis warn that snoring may be a warning sign of underlying heart issues, citing five key reasons.
Persistent, loud snoring is often dismissed as a harmless nighttime habit, but it can be a warning sign of obstructive sleep apnea (OSA), a condition that puts the heart under constant stress. According to leading medical experts, OSA can lead to high blood pressure, irregular heart rhythms, and eventually, heart failure. Dr. Varun Bansal, a senior consultant at Indraprastha Apollo Hospitals, states that snoring is frequently trivialized, yet its impact on the body is profound, and is strongly linked with changes in the way the heart and blood vessels work.
Experts have identified five critical ways that chronic snoring and sleep apnea damage the cardiovascular system:
- Oxygen deprivation and heart stress: When snoring transitions into sleep apnea, the airway becomes blocked, causing breathing to stop for seconds or even a minute, leading to a state of emergency and triggering stress systems that spike the heart rate.
- The link to ‘stubborn’ high blood pressure: Blood pressure stays elevated or surges during apnea episodes, making the heart muscle stiff and less functional over time.
- Dangerous heart rhythm disturbances: The repeated ‘stop-start’ nature of breathing during sleep stimulates stress hormones like adrenaline, increasing the risk of Atrial Fibrillation (AFib) and other irregular heartbeats.
- Inflammation and vascular damage: Repeated breathing pauses trigger systemic inflammation, damaging the lining of the blood vessels and speeding up plaque buildup (atherosclerosis), which can lead to heart attacks and weakened heart function.
- The ‘vicious cycle’ of metabolic stress: Snoring is tightly correlated with abdominal obesity and diabetes, and sleep disruption interferes with hunger hormones, leading to weight gain, which in turn worsens snoring.
The warning signs of sleep apnea that shouldn’t be ignored include daytime fatigue, gasping for air or choking sounds during sleep, morning headaches, and high blood pressure that doesn’t respond well to medication. While occasional snoring due to a cold or alcohol use is generally not dangerous, doctors urge a medical evaluation if snoring is accompanied by these symptoms.
The good news is that heart damage caused by sleep apnea is often preventable and sometimes reversible if caught early. Treatments like CPAP devices, weight management, and lifestyle changes can stabilize heart rhythms and lower blood pressure. If you or a loved one are chronic snorers, a sleep study could be the first step in protecting your heart’s future. It’s essential to seek medical advice if you’re concerned about snoring or sleep apnea, as early detection and treatment can make a significant difference in preventing long-term heart damage.
Glenmark Pharmaceuticals USA has introduced a multiple-dose vial of epinephrine injection.
Glenmark Pharmaceuticals Inc, USA, has launched Epinephrine Injection USP, a bioequivalent and therapeutically equivalent product to the reference listed drug manufactured by BPI Labs, LLC. The product is available in a 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial and is intended for the U.S. market. According to IQVIA sales data, the Epinephrine Injection market had annual sales of approximately USD 67.6 million for the 12 months ending October 2025. This launch expands Glenmark’s institutional product portfolio and reinforces its commitment to providing high-quality, affordable treatment options.
Glenmark Pharmaceuticals Limited is a prominent Indian multinational pharmaceutical company that has been in operation since 1977. The company has grown from its origins in generic medicines and active pharmaceutical ingredients (APIs) to become a research-led global healthcare organization with a presence in over 80 countries. Glenmark’s core therapeutic expertise includes respiratory, dermatology, oncology, cardiovascular, and anti-infective treatments, with multiple R&D centres and manufacturing facilities across India and internationally.
In recent years, Glenmark has diversified into innovative drug development and biosimilars, while maintaining a strong portfolio of branded generics in high-growth markets. The company has also entered strategic collaborations and licensing deals to advance novel therapies, particularly in oncology. Despite facing quality control challenges in some manufacturing facilities, Glenmark continues to pursue a transformation towards a more innovation-centric business model aimed at increasing its branded portfolio and long-term global competitiveness.
The launch of Epinephrine Injection USP is part of Glenmark’s strategy to strengthen its institutional channel presence and improve access to essential medicines. According to Marc Kikuchi, President and Business Head for North America at Glenmark, the launch supports the company’s commitment to providing high-quality, affordable treatment options. With its robust revenue growth and expanding demand in key markets such as North America and Europe, Glenmark is well-positioned to continue its growth and expansion in the global pharmaceutical market.
The US FDA has issued a recall for an antifungal shampoo manufactured by Sun Pharma.
The US Food and Drug Administration (USFDA) has announced a recall of over 17,000 units of antifungal shampoo, Ciclopirox Shampoo, due to manufacturing issues. The recall was initiated by Taro Pharmaceutical Industries, the US arm of Sun Pharma, on December 9. The shampoo is used to treat seborrheic dermatitis, a condition that causes dry, flaky, and itchy skin. The recall was classified as a Class II recall, which means that the product’s use may lead to temporary or medically reversible health consequences, but the likelihood of serious adverse health outcomes is minimal.
The recall was due to “failed impurity/degradation specifications,” according to the USFDA. Taro Pharmaceutical Industries is a private company and a wholly-owned subsidiary of Sun Pharma, which acquired the Israel-based company in a deal valued at $347.73 million last year. Sun Pharma has been the majority shareholder of Taro since 2010. Taro primarily focuses on dermatology and produces a wide range of prescription and over-the-counter products.
The recall is a setback for Sun Pharma, which is a leading exporter to the US market. In the second quarter of FY26, the company reported revenue of Rs 14,478 crore, with a net profit of Rs 3,118 crore, a 2.56% increase year-on-year. However, formulation sales in the US declined 4.1% to $496 million. The recall highlights the importance of quality control and regulatory compliance in the pharmaceutical industry.
The USFDA’s Enforcement Report noted that the recall was nationwide and affected 17,664 units of the Ciclopirox Shampoo. The company has taken prompt action to address the issue, and the recall is expected to minimize any potential harm to consumers. The incident serves as a reminder of the need for pharmaceutical companies to maintain high standards of quality and manufacturing practices to ensure the safety and efficacy of their products.